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Zinc-metalloproteinases play a key role in the biosythesis and metabolism of different 
bioactive peptides. As a member of zinc-metalloproteinases, thermolysin has served as a 
model system to study the inhibition mechanism of other metalloproteinases. Inhibitors of 
thermolysin have considerable potential as therapeutic agents. In the present master thesis, 
docking calculations were performed and reported for 25 potent non-peptidal thermolysin 
inhibitors retrieved from literatures.  Docking software ICMTM was used. 8 out of 25 
compounds were from X-ray crystal structure complexes with thermolysin. ICMTM 
reproduced 63% of the binding modes from 8 X-ray crystal complexes. Experimental assay 
were done with MS, R and M compounds. 2 out of 13 MS compounds were found to inhibit 
thermolysin (one was later found to be competitive inhibitor and the other one was found to 
be a non-competitive slow inhibitor). 12 out of 37 R compounds inhibited thermolysin with 
varying affinity and 2 out of 7 M compounds had thermolysin inhibition property. One of 
them was found to be very potent inhibitor, with IC50 value of 4,411x10-11 mM. Docking 
calculations were performed with all MS and active R compounds to predict the binding poses. 
However, the experimental verification showed that only two of the MS compounds are 
thermolysin binders. For R compounds, the correlation between binding energies and IC50 is 
not linear, which indicates that the docking poses were not yet ‘perfect’. The presence of 
metal ions as zinc is a problem for docking studies. Parameterization of zinc ion need to be 











ACE  Angiotensin-converting enzyme;  
CATH             Classes/ Architecture/ Topology / Homologous Superfamily; 
CoV   Coronavirus;  
DMF  Dimethyl formamide 
EC  Enzyme Commission; 
ECE  Endothelin converting enzyme; 
ECE-I              Endothelin converting enzyme I;  
ECM  Extracellular matrix; 
EMBL             European Molecular Biology Laboratory; 
FAGLA          FA-glycyl-L-leucine amide  
HTS        High-throughput screening; 
IC50                          The 50% inhibitory concentration of a substance 
ICM  Internal coordinate mechanics; 
KD                  Dissociation constant; 
Ki                    Inhibition constant; 
LMWP Low molecular weight protamine; 
MD  Molecular Dynamics;  
MEROPS        An information resource for peptidases 
MMPs      Matrix metallopeptidases;  
MMFF  Merck Molecular Force Field 
Mr                   Relative molar mass; 
NEP  Neprilysin; 
NMR  Nuclear Magnetic Resonance; 
NP                  Bacillus subtilis  
PDB  Protein Databank; 
RMSD             Root mean square deviation;  
SARs  Structure-activity relationships; 
SARS  Acute respiratory syndrome;  
SFs                  Scoring functions; 
TLN         Thermolysin; 
TLPs  Thermolysin -like peptidases; 
VLS        Virtual ligand screening; 
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1.1 Proteinases in general 
  In 1946 Linus Pauling first formulated the basic principle underlying enzyme catalysis, 
namely, that an enzyme increases the rate of chemical reaction by binding and stabilizing the 
transition state of its specific substrate tighter than the ground state [1]. The presence of 
enzymes may increase the biological catalyzed reaction by factors of 1015, while 
enhancements in the range 10 3 -10 9 are more typical [2]. Proteinases are widely distributed 
enzymes in nature, where they perform a variety of different functions. They selectively 
catalyze the hydrolysis of polypeptide bonds. In higher organism, proteinases are involved in 
regulating physiological processes such as control of blood pressure, immunological defense, 
wound healing, digestion, fertilization, differentiation, growth, cell signaling and migration, 
apoptosis, and blood clotting [1].  All the well-characterized proteinases so far, belong to one 
or other of families classified by MEROPS (http://MEROPS.sanger.ac.uk/). They are aspartic, 
cysteine, glutamic, metallo-proteinases, serine, threonine proteinases and others of unknown 
catalytic type [3]. This classification is based on a functional criterion, namely, the nature of 
the most prominent functional group in the active site. Proteinases are also classified by clan. 
According to MEROPS, a clan contains all peptidases from a single evolutionary origin. It 
represents one or more families that show evidence of their evolutionary relationship by 
having similar tertiary structures, or by the order of catalytic-site residues in the polypeptide 
chain and often by common sequence motifs surrounding the catalytic residues [3]. Clan MA 
contains a variety of metallopeptidases (Table1.1). The metallopeptidases in family M2,M4 
and M13 have been subjects of particularly intense research. 
 
Table 1.1: Types of pepidase activity within MA clan. 
Aminopeptidase A( M1, M61 ) 
Carboxypeptidase ( M2, M32 ) 
Peptidyl-dipeptidase ( M2 ) 
Oligopeptidase ( M3, M13 ) 
MA 





Zn2+ containing metalloproteinases constitute an expanding list of structurally related 
proteases which are widely distributed in nature. They are involved in biochemical events of 
extreme importance, such as digestion (carboxypeptidase A, astacin), tissue remodeling and 
extracellular matrix (ECM) degradation (matrix metalloproteinases, MMPs), blood-pressure 
regulation (neprilysin), formylation and deformylation in bacterial protein synthesis (peptide 
deformylases), etc. [4]. In last decades, zinc peptidases with known 3D structure have 
attracted increased attention for structure-based design of drugs [5, 6] used for treatments of a 
number of diseases such as infectious disease, hypertension,  tumor invasion, arthritis and 
bone destruction. Metalloproteinases are the most diverse of the eight main types of 
proteinases, with 76 families identified so far [3]. 
 
1.3 TLN family 
A family is a set of homologous peptidases. The proteins that have evolved 
evolutionarily from a common ancestor are said to be homologous [7]. Although the sequence 
similarity in homologous proteins is less preserved, 3D structures of homologous proteins 
have been remarkably conserved during their evolution, because the common structure is 
crucial for the specific function of the protein [1]. Thermolysin (TLN, EC 3.4.24.27) belongs 
to a family of metalloproteinases [3] that chemically function at neutral pH [8]. It is a 
bacterial endopeptidease of M r  34,600 containing 316 residues in its single polypeptide chain 
[9].  
 
Figure 1.1: TLN structure in ribbon mode (PDB: 1gxw, 316 residues), domain 1 (blue) and domain 2 (red).  
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TLN is an endopeptidase rather than an exopepetidase. This is manifested in the nature 
of the binding site, instead of a deep pocket as in carboxypeptidases [10], TLN has an open 
extended cleft that can bind the polypeptide chain of the substrate on both sides of the peptide 
bond which would be cleaved (this bond named as scissile bond) [9, 11]. According to CATH 
(Classes/ Architecture/ Topology / Homologous Superfamily) protein structure classification 
(http://www.cathdb.info/latest/index.html), this wide cleft separates TLN into two large 
domains (Figure 1.1). Table 1.2 shows more detailed classification based on secondary 
structure elements (α helix and β strand). 
  
Table 1.2: The CATH Structure classification of TLN [12] (PDB: 1gxw). 
Domain CATH NO Class Architecture 
Start 
Res 
Stop Res Length 
1 3.10.170.10 αβ  Roll 6 154 149 
2 1.10.390.10 Mainly α Orthogonal Bundle 155 315 161 
 
Ramachandran plots of TLN (Figure 1.2) show that 96.5% (303/314) of all residues 
are in energetically favored light blue regions [13]. Further more, it is evident that higher 
proportion of amino acids is distributed in the lower left quadrant which refers to right handed 
α-helix. Whereas amino acids fall in the upper left quadrant form the β strands, another major 
secondary structure elements. 
 
 
Figure 1.2: Ramachandran plots showing the preferred combinations of the torsion angles phi (Ф) and psi (Ψ) for 




There are some important features in the TLN active site (shown in Figure 1.3).  
 The active site zinc ion is coordinated by three amino acid residues and a water 
molecule at two alternative positions [14]. These amino acids include two histidines 
(His142, His146) and a glutamic acid (Glu166).  
 In addition, one glutamic acid residue (Glu143) and one histidine residue (His231) 
interact with a water molecule at the active site and are required for catalysis [15, 16]    
 
Figure 1.3: Catalytic site of TLN indicating the water molecule at two alternative positions.  
 
The crystal structure complex of the enzyme with one thiocyanate ion in the active site, 
has been solved [17] (PDB code; 1gxw). The structure of TLN contains a single catalytic zinc 
ion that is essential for hydrolytic activity, and four calcium ions that are required for 
thermostability [18]. This extracellular endopeptidase catalyses hydrolysis of the peptide bond 
specifically on the imino side of large hydrophobic residues [19, 20], in particular leucine, 
isoleucine and phenylalanine. 
According to the results from European Molecular Biology Laboratory (EMBL) 
www.ebi.ac.uk , TLN active site reside between helix 3 and helix 4 (Figure 1.3). Helix 3 starts 
with Ile137, ends with Tyr151. Both of the helices fall in lower left quadrant of the 
Ramachandran plot (Figure 1.2, Right), which indicates highly conserved sequence residing 
in energetically favorable region [1]. Helix 4 starts with Asn159, ends with Tyr179. Two 
kinds of turns, β-turn (Tyr151-Gly154) and γ-turn (Ile156-Gln158) connect these two helices. 
Turns play an important role in globular proteins from both structural and functional points of 
view [1]. A polypeptide chain cannot fold into a compact structure without the component of 
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turns. In TLN, these turns occur on the exposed surface and hence form the side of peptide 
loading grove. 
The TLN family is the proteinase family M4 of the MA clan of metalloproteinases [3]. 
Other TLN-like metalloproteinases (TLPs) such as, neprilysin (NEP) [21], angiotensin 
converting enzyme (ACE), and endothelin converting enzyme I (ECE-I) [22] regulate the 
cardiovascular system in human physiology. These enzymes do not belong to the M4 family 
but have huge mechanistic and structural similarities with TLN as well as other 
metalloproteinases. Characterization with peptide substrates and high performance liquid 
chromatography analysis of β-casein digests shows that the M4 family is a homogeneous 
family in terms of catalysis, even though there is a significant degree of amino acid sequence 
variation [23]. They posses a consensus sequence HEXXH that constitutes the zinc-containing 
catalytic domain [5, 24]. Based on similarities on catalytic site mentioned above, TLN have 
served as a test vehicle to identify proposed inhibitor interactions within the active site of 
zinc-metalloproteinases [5, 25].  
 
1.3.1 Therapeutic possibilities of TLN like enzymes 
Among the enzymes associated with human pathogenic fungi and bacteria, TLPs seem 
to play a predominant role during pathogenesis and cause increases in vascular permeability, 
hemorrhagic edema, and sepsis [26, 27]. TLPs of the M4 family such as aureolysin, 
pseudolysin, and bacillolysin are virulence factors of diverse bacterial pathogens [28]. They 
promote development within the infected host, and they are used to suppress or avoid its 
innate immune system [28], while TLN functions intracellulary for bacterial nutrition 
purposes [29]. A recent study of the cell entry mechanism of Acute respiratory syndrome-
coronavirus (SARS-CoV) reveals that proteases such as trypsin and TLN facilitated a 100- to 
1,000-fold higher efficient SARS-CoV infection than without these proteases [30]. TLN like 
proteinases are also key factors in the pathogenesis of various diseases, including several 
types of bacterial infections [31-33], cholera [34], gastritis and peptic ulcer [35] and gastric 
carcionoma [36]. Since particular metalloproteinases associated with human pathogens have 
been recognized as prominent virulence factors, their therapeutic inhibition has become a 
novel strategy in the development of second-generation antibiotics [37, 38]. On the other hand, 
in an attempt to reduce severe adverse reactions of protamine in cardiovascular surgeries, Lee 
[39] and his colleagues developed in vitro low molecular weight protamine (LMWP) as a 
potentially effective and less toxic heparin antagonist by using enzymatic digestion of 
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protamine with TLN. Animal test showed that it could completely neutralize all these 
different anticoagulant functions of heparin in dogs. These preliminary findings indicated that 
LMWP could potentially provide an effective and safe means to control both heparin- and 
protamine-induced complications[39]. 
 
1.3.2 Industrial applications 
Natural enzymes are attractive as catalysts in industrial processes. They are often more 
effective and selective, and produce more pure products with minimal wastage. Proteinases of 
the TLN family have many unique characteristics with a huge potential for industrial 
processes. Besides a purely physiological activity, TLN has also been found to be a useful 
catalyst in protein engineering [40, 41].  
Enzyme characteristics of TLN family include,  
 Thermophilic enzymes with catalytic activity at temperatures up to 80°C;  
 Enzymes that exhibits maximum activity under extreme alkaline conditions [42]; 
 Enzymes with high stability in organic solvents such alcohols [43]; and enzymes being 
unique due to their strict substrate specificity [44].  
 A bioinformatic study of Vibriolysin from  Antartic bacterium strain 643 (VAB) has 
shown that VBA has the structural features of a cold adapted protein [45]. Several enzymes of 
the TLN family are already in industrial use. TLN is used as a bio-catalyst in the synthesis of 
the artificial sweetener aspartame, as a peptide and ester synthetase, and as a non-specific 
proteinase to obtain fragments for peptide sequencing [46-48]. Vimelysin from  Vibrio 
str.T1800, has a potential application in peptide condensation reactions [49], while vibriolysin 
from Vibrio proteolyticus is used in the production of aspartame and for removal of necrotic 
tissue from wounds such as burns or cutaneous ulcers [50]. 
 
1.3.3 A model system for other metalloproteinases       
            The zinc-metalloproteinases secreted by the gram-positive thermophilic bacterium 
Bacillus thermoproteolyticus [3] is the prototype of the TLN family and has served as a model 
system to study the inhibition mechanism of other metalloproteinases. Crystallographic data 
for TLN and various TLN-inhibitor complexes have been used in efforts to model the active 
site of other TLN-like enzyme [25, 51]. Because Zinc-metalloproteinases play a key role in 
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the biosythesis and metabolism of different bioactive peptides, inhibitors of these enzymes 
have considerable potential as therapeutic agents [52]. 
 Angiotensin I-converting enzyme (ACE, EC 3.4.15.1) belongs to the M2 family of 
Zinc-binding metalloproteinases, within the MA clan [3]. ACE plays an important role in 
blood pressure homeostasis by cleaving the C-terminal dipeptide from angitensin I to produce 
the potent vasopressor peptide angiotensin II [53]. In addition, ACE inactivates the vaso 
dilatory peptide bradykinin by the sequential removal of two C-terminal dipeptides [54]. ACE 
contains two Zinc-coordinating catalytic domains (N and C domains) each bearing the 
HEXXH motif where the two histidines form two of the three amino acid ligands, while a 
glutamate 24 residues downstream forming the third ligand [55]. Apart from the HEXXH 
motif, root mean square deviation (RMSD) of the Zinc-binding sites between TLN and ACE 
is 0.52Å [56]. The role of a Zn ion in ACE catalysis was thought to be analogous to that in 
TLN [57]. As a consequence of these structural and functional similarities and the role of 
ACE in the metabolism of those two vaso active peptides, the active site of TLN has been 
used as a model to develop highly potent and specific ACE inhibitors. These inhibitors have 
been used as orally active drugs in the treatment of hypertention and congestive heart failure 
[58].  
 Neprilysin (neutral endopeptidase; NEP, EC 3.4.24.11) is an integral plasma 
membrane ectopeptidase of the M13 family of Zinc metalloproteinases [3]. Like TLN and 
ACE, NEP possesses the HEXXH motif as well as  a consensus sequence EXIXD in which 
the glutamate (Glu) serves as the third Zn ligand [55]. NEP is involved in the metabolism of  a 
number of regulatory peptides of the mammalian cardiovascular, inflammatory, nervous and 
immune systems [59]. So, NEP is potential therapeutic targets in cardiovascular and 
inflammatory disorders. Before the crystal structure of NEP-inhibitor complex was solved, the 
structure and function similarities between NEP and TLN served as the basis of NEP inhibitor 
design by using TLN as a test model. Selective inhibitors, such as phosphoramidon have 
contributed to understanding NEP enzyme function [52].  
 The merits of modeling proteins based on homology to a known structure have been 
applied a decade ago [60], and it is clear that model building by homology is a valuable 
technique to construct three dimensional coordinates of protein structures when the sequence 
identity between the model and the structure is high [7]. With 47% sequence identity with the 
neutral protease of Bacillus subtilis (NP-sub), TLN was used as main structural template to 
build and optimize a three-dimensional model of NP-sub in associated with site-directed 
mutagenesis techniques [61].  
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1.4 TLN and ligand interactions 
1.4.1 The catalytic site of TLN and HEXXH motif 
TLN is one of the most studied metalloenzymes and, for a number of free enzyme and 
enzyme-inhibitor complexes, detailed X-ray structures have been obtained. The first was 
published in 1972 [62]. These structures show that the zinc-binding residues are His142, 
His146 and Glu166, while Glu143 act as the catalytic residue (Figure 1.4). There is a distorted 
tetrahedral coordination of the Zn ion of TLN, where one position (the fourth) is exposed to 
solvent water and turns out to always be present for catalytic zinc metalloproteins [63-65]. 
The Glu143 residue, which is positioned in the second coordination shell of the zinc cation, 
forms together with the above-mentioned two histidines the consensus HEXXH motif of the 
enzyme amino-acid sequence[4]. Although the overall sequence and backbone conformations 
of the related enzymes display very different binding modes, the zinc-binding HEXXH motif 
is highly conserved between all the members of clan MA, thus implying evolutionary 
converged or inherited reaction mechanisms [4, 6]. 
                                       
Figure 1.4: The TLN active site structure(PDB:1gxw), generated from X-ray data[17]. 





       Jongeneel [66] identified mono-catalytic zinc metallopeptidases from a number of 
families. The Zn2+ is bound by a glutamate (Glu166), 20-33 residues C-terminal to the 
HEXXH motif. The metallopeptidases in which the zinc is bound by HEXXH+Glu are known 
as 'Glu-zincins' (Figure 1.5). The Zn2+ is tetrahedrally coordinated, and the fourth ligand is a 
water molecule which forms the nucleophile in the catalytic process [67]. Four M4 family 
members have been crystallized and the 3D structure solved. Their sequence has been 
compared (Figure 1.5).  
 
 
Figure 1.5: Structural alignment of some members of this 'Glu-zincins'. The 3D structures were taken from 
Brookhaven Protein Databank (PDB, codes 1tlp, 1npc, 1ezm, and 1bqb) where the box is showing the highly 
conserved active site motif HEXXH (+Glu). Green boxes stand for β sheets and red boxes refer to α helixes. 
 
 
Figure 1.6: The folding pattern of the HEXXH motif in the three-dimensional space of the protein (PDB: 1gxw). 
 
The families of clan MA are united by the presence of an HEXXH motif (Figure 1.6) 
in which the two His residues are zinc ligands and the Glu has a catalytic function [3]. The 
fourth ligand is a molecule of water that becomes activated and mediates the nucleophilic 
attack on the scissile peptide bond (Figure 1.3). 
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Nevertheless, it is important to recognise that the pentapeptide HEXXH also occurs in 
many proteins that are not peptidases. Other non-peptidase proteins contain motif HEXXH 
too, but a more specific motif can be defined for clan MA. A longer consensus sequence that 
is more reliable in detecting metallopeptidases was described by Jongeneel et al. [66] and 
further refined by Rawlings and Barrett [68]. 
In the folded metallopeptidases, the HEXXH motif is part of a helix-turn-helix region 
around the active site, and this turn is required between the two helices to bring the ligands 
together (Figure 1.4).  
 
1.4.2 The catalytic mechanism 
Despite extensive crystallographic studies, site-directed mutagenesis and kinetic 
investigations accumulated for TLN and homologous enzymes over the years, the catalytic 
reaction mechanism is still under debate, particularly regarding to which amino acids that take 
part in catalysis. Usually, Glu143 was originally considered a proton donor, but later 
considered to be an electrophile [69]. Other residues found to be essential for catalysis are 
Tyr157, Asp226, and His231 (Figure 1.7).  
 
Figure 1.7: The TLN active site structure(PDB:1gxw), generated from X-ray data[17].    
                        
      The residue His231 is  proposed to be the proton donor and general base, while Asp226 is 
thought to orient the imidazolium ring of His231 by the salt bridge between either OD1 and 
OD2 of Asp226 and ND1, N of His231 [9, 45, 67] . 
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      Tyr157 is suggested to act as a general acid and thereby contribute to positioning the 
nucleophilic water molecule. Asp226 is completely conserved amongst M4 or all 
metallopeptidases [70]. 
 
1.5 Experimental studies of enzyme inhibition 
1.5.1 Enzyme inhibition 
Compounds that influence the rates of enzyme catalyzed reactions either reduce the 
rate (inhibition) or increase the substrate turnover (activation). Accordingly, the compounds 
are termed inhibitors or activators. Enzyme inhibition plays a vital role in controlling catalytic 
reaction. A number of techniques are used for searching the basic explanation of the 
mechanism of a substrate involved in enzymatic reactions. On the basis of these kinetic 
observations, inhibitors are usually divided into two main classes, reversible and irreversible, 
depending upon the manner in which the inhibitor is attached to the enzyme [2]. The 
reversible inhibitors form noncovalent interactions with the enzyme surface, which can be 
easily reversed by dilution or dialysis, while the irreversible inhibitors interact with functional 
groups on the enzyme surface by forming strong covalent bonds that often persist even during 
complete protein breakdown [71].  
The relationship between a single substrate and enzyme concentration was interpreted 
in 1913 by Leonor Michaelis and Maud Menten with their classic Michaelis-Menten kinetics 
(Equation 1.1) [72] .  
v = [ ][ ]SK
SV
m +
max  ………………………………..…………………………………………………… (1.1) 
Vmax-maximum rate, Km-Michaelis-Menten constant, v-reaction rate, [S]-substrate concentration. 
The prerequisite of this kinetic model is that the concentration of enzyme is much 
lower than the concentration of substrate [S] (i.e. where enzyme concentration is the limiting 
factor), and when the enzyme is not allosteric. From equation (1) we know that the reaction 
rate v is the number of reactions per second catalyzed per mole of the enzyme. The algebraic 
rearrangement of the Michaelis-Menten equation is the mathematical basis for deducing 
Lineweaver-Burk plot [73]. Lineweaver-Burk analysis is one method of linearizing substrate-
velocity data so that the kinetic constants Km and Vmax can be determined. The reaction rate 
increases with increasing substrate concentration [S], asymptotically approaching the 
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Figure 1.8: Reaction rate V as the function of substrate concentration [S]. 
 
Figure 1.9: Lineweaver-Burk analyses of 1/ V vs. 1/[S].  
  
Although this technique has been widely applied to study various enzyme systems, its 
utility is somewhat limited because it is most appropriately applied to enzymes that utilize 
only a single substrate.  In vivo, a common form of enzyme inhibition involves the 
competition between substrate and inhibitor for an active site. This is also the case involved in 
the interfering or removal of TLN disease related activity on its substrate by introducing 
inhibitors. All the ligands used in this thesis contain common TLN zinc binding groups 
(ZBG): carboxyl, hydroxyl, sulphydryl, dialkylsilanediols or phosphonate. We assume that 
they all are competitive inhibitors; so that they compete with the substrate for the active site 
of the TLN with their ZBG. By forming an inactive enzyme-inhibitor complex, they decrease 
Y intercept = 1/ V max  
X intercept = -1/ K m  
Slope          = K m / V max  
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the rate of catalysis. Therefore, the Michaelis-Menten equation for the rate (v) of an enzyme 



















max ……………………………………………………………………... (1.2) 
where it shows that, in the presence of inhibitor, the extent to which the reaction is slowed is 
dependent on the inhibitor concentration [I] and the dissociation constant, Ki, for the enzyme 
inhibitor complex. It is seen that, smaller K i  value indicates strong binding of the inhibitor to 
the enzyme. But with competitive inhibitor, the inhibition may be overcome, at a fixed 
inhibitor concentration, by increasing the substrate concentration.  
 
1.5.2 IC50 values and affinity prediction 
In the initial screening of inhibitors, it is convenient to compare affinities within tested 
compounds as percentage inhibition. An IC50 value (Concentration of inhibitor required to 
inhibit enzyme activity by 50% in vitro) is a convenient measure of potency. The IC50 of a 
drug can be determined by constructing a dose-response curve and examine the effect of 
different concentrations of antagonist (inhibitor) on reversing agonist (substrate) activity. This 
is called a functional inhibitor assay [74]. In the present study a single concentration of the 
substrate [FA-glycyl-L-leucine amide (FAGLA)] was used in every assay tube for the 
competition binding assays. The level of specific hydrolysis of the FAGLA was then 
determined in the presence of a range of concentrations of putative inhibitors, in order to 
measure the concentration with which they could compete with FAGLA for the binding. 
Competition curves may also be computer-fitted to a logistic function to reduce the 
calculating time.  
The IC50 value is converted to an absolute inhibition constant Ki by using the Cheng-












S1 ……………………………………….…………….………… (1.3) 
Where Ki is the inhibition constant for a drug, and indicates the binding affinity of the 
inhibitor. [S] is substrate concentration and Km is the affinity of the substrate for the enzyme. 
Whereas the IC50 value for a compound should be used with care when comparing inter 
laboratory results for competitive inhibition, because it is dependent on the substrate 
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concentration and the assay you are using. For non-competitive and uncompetitive inhibitors, 
IC50 equals Ki value and is independent of substrate concentration. Ki is independent of 
substrate and inhibitor concentrations for all classes of reversible inhibitors [76]. 
 
1.6 Theoretical studies of protein ligand-interactions 
1.6.1 Docking 
Structure based drug design approaches have increasingly demonstrated their value 
since the first biologically relevant X-ray structures became available 30 years ago. The 
impact of these methods and technologies on early lead discovery and lead optimization is 
significant. Protein-ligand docking aims to predict and rank the structure(s) arising from the 
association between a given ligand and a target protein of known 3D structure [77]. Pioneered 
during the early 1980’s [78], it remains a field of vigorous research, having become a useful 
tool in drug discovery programs [79]. In particular, protein-ligand docking occupies a very 
special place in the general field of docking, because of its applications in medicine [80]. 
From the docking of both protein and ligand as rigid bodies [78], protein-ligand docking has 
developed to an area where full flexibility on the ligand is commonly evolved. Even though 
protein flexibility is known to increase affinity between a given drug and its target [81], and 
the fact that proteins are in constant motion between different low energy conformational 
states. Protein flexibility has not been well considered by new docking programs (Table 1.3). 
Furthermore, binding orientation and binding-site location can be greatly influenced by 
protein flexibility. The traditional lock-and-key and induced-fit theories have given their way 
to more modern theories that bestow a greater weight to the receptor flexibility issue [82]. The 
current idea interprets a protein as an ensemble of differently populated conformational states 
in equilibrium, rather than the stable conformation appearing in X-ray crystal structure [82]. 
An important notion that needs attention is that the conformation of receptor in the protein-
ligand complex are not necessarily the most populated conformations in an unbound state [81-
83]. So, when it comes to docking, these aspects imply that instead of targeting a single pose 
of a given ligand on a single receptor structure, one should ideally look for the most populated 
alternatives from an ensemble of solutions comprising several different binding 





Table 1.3: Most common used ligand-protein docking programmes, official website, docking algorithms, scoring 
function and system compatibility. 
Note: MC, Monte Carlo method; GA, genetic algorithm; ICA, Incremental construction algorithms;  HSS, hierarchical systematic search 
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There are currently more than 49,000 (by Mar 11, 2008) crystallographic or NMR 
structures of proteins or nuclei acids available from the Protein Data Bank (PDB) [110], and 
the rate of 3D macromolecular structure determination continues to increase every year, 
particularly with the development of new techniques such as high-throughput X-ray 
crystallography [111]. Many of these macromolecules play vital roles in critical metabolic 
pathways and may be regarded as potential therapeutic targets, offering unparalleled 
opportunities for structure-based drug design and discovery. In this context, the ideal of using 
a high resolution structure of a target protein to design the perfect ligand binding modes is 
challenging. Completely de novo design of a lead molecule produced clinical candidates as 
zanamivir, commercial name RELENZA® , by GlaxoSmithKline company against common 
cold [112], and AG-331 as an anti-cancer drug [113].  
In terms of protein-ligand docking methods, the goals can be rationalized as first, 
search for precise ligand conformations and poses by minimizing the total energy of the 
protein ligand complex, within a given targeted protein when the structure of the protein is 
known or can be estimated. Second, to predict the binding affinity of any protein ligand 
complex. 
So, docking, as a result, usually involves two independent steps:  
 Determining the orientation of a ligand relative to the receptor.  
  Evaluate (score) the ligand orientation. 
 
1.6.2 Scoring 
The binding affinity prediction problem denotes the question of how well the ligands 
bind to the protein (scoring) [77]. In a biological environment, the system would include not 
less than the solvent molecules, the ligand, and the macromolecular receptor. Solvent 
molecules are commonly excluded from docking approaches, because of the tremendous 
number of degrees of freedom with the solvent molecules, or in special cases implicitly 
modeled in the scoring functions as a way to address the solvent effect. However, even the 
remaining part of the system - ligand and receptor - has a computational untreatable number 
of degrees of freedom, and therefore, the dimensionality of the problem has to be reduced 
through the application of different approximations, allowing the search space to be more 
effectively sampled.  
In the last 15 years, a number of scoring functions (SFs) have been reported and 
implemented in docking programmes. The SFs of most often used docking programs are 
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listed in Table 1.3. In general, SFs attempt to predict the binding free energy or to rank-order 
compounds by their bioactivity. These SFs are classified as force field (FF)-based, empirical 
and knowledge-based [114-117]. Since the accuracy of SFs plays key role in a successful 
docking approach [118], numerous progress over the years has been made. However, 
commonly used SFs are known to have limitations as the protein-ligand complex often 
includes subtleties not captured by SFs [119]. The SFs should enable the distinction between 
the true binding modes and all the other alternative modes explored, or between active and 
random compounds. However, a very rigorous scoring function would be computationally too 
expensive, rendering the analysis of the several binding modes unfeasible. While, many 
oversimplifications, in the name of speeding up screening time, are believed to be one of the 
main causes of poor ranking. This in turn, causes major difference of docking successfulness 
of different docking programmes (Figure 10). For this reason, the lack of a suitable scoring 
function, both in terms of speed and accuracy, is the major bottleneck in docking [79]. To 
overcome this hurdle, it is ideal to combine several more scoring methods in docking 
programmes. For example, ChemScore and GoldScore have been implemented in GOLD.  














































































Figure 10: Comparative studies of different docking program, reporting the present of docked compounds within 
an RMSD of 1 and 2 Å from corresponding X-ray structure. 
                  
  Perola et al.,2004          Bursulaya et al., 2003             Friesner et al., 2004      Chen et al., 2006  
 26
1.6.3 Different programs 
The Internal Coordinates Mechanics ICM™ program (www.molsoft.com) [121] 
performs flexible ligand docking using a Monte Carlo minimization procedure in internal 
coordinates to find the global minimum of the energy function. It is also fit for protein-protein 
docking. Some frequently used protein-protein docking programs are listed in Table 1.4. The 
ICM program was compared with AutoDock, DOCK, FlexX, and GOLD in several studies 
[122, 123]. ICM program provided the highest accuracy and  has also outperformed DOCK 
and FlexX in virtual library screening tests [122].  
        Molecular docking methodologies ultimately seek to predict (or often retrospectively 
reproduce) the best mode by which a given compound fit into a binding site of a 
macromolecular target. On the basis of the results for this data set, ICM therefore appears to 
be the most versatile VLS and Docking tool. Comparing low throughput approaches (those 
based on molecular dynamics), until now, more than 60 docking programmes and over 30 
scoring functions have been developed [124].  
 
Table 1.4: Commonly used protein-protein docking programs. 
 
Software Algorithm 
ICM [121] Force field 
CHARMM [103] Force field 
MolFit [125] Fast Fourier Transformation 
FTDOCK [126] Fast Fourier Transformation 
DOT [127] Fast Fourier Transformation 
Hex [128] Shortest path first 
ZDOCK [129] Fast Fourier Transformation 




BiGGER [131] Global scoring function 
GAPDOCK [132] Genetic Algorithm Approach 
Surfdock [133] 
Fourier correlation of spherical 
harmonics 
GRAMM [134] Fast Fourier Transformation 
PatchDOCK [106] 




2 Aims of the study  
It is clear that for any modeling strategy to be validated, it must at the very least 
rationalize (either qualitatively or semi-quantitatively) the existing structure-active 
relationships (SARs). Furthermore, it must be capable of making predictions (either extending 
SARs or leading to the birth of new SARs) that can be tested through feasible experimental 
strategies. An essential component of the development of such a model is the availability of 
reliable biological assays which preferably yield consistently reproducible results and which 
are based on a finite number of mechanisms. Thus, inhibition of binding by a group of ligands 
to an enzyme would constitute an excellent example of a reliable assay which could form the 
basis of the pharmacophore design and protein inhibitors library building. We gathered a 
certain amount of test compounds from several of our collaborators. The main goals of this 
task fall in: 
 Determine the molecular interactions of inhibitors from the literature with TLN by 
using docking and scoring. 
 Discover novel TLN inhibitors by using experimental and theoretical approaches. 
 Determine the molecular interaction of these inhibitors with TLN. 
As computational potency and knowledge are constantly increasing, the integration of 
ICM™ program with experimental assays would make it compatible with current trend in 












3.1 In vitro experiment 
3.1.1 Chemicals and compounds 
All the chemicals used for the binding assays were purchased from Sigma-Aldrich 
(US); three-times crystallized thermolysin was purchased from CalBioChem (E-Merck, 
Germany). The tested compounds  were from different collaborators on the basis of joint 
collaborative research projects. MS compounds are from Prof. Mukhlis Sultankhudzaev, 
Uzbek Academy of Science, Tashkent, Uzbekistan; R compounds are from Dr. Rasool Khan, 
Department of Chemistry, University of Peshawar, Pakistan; M compounds are from Dr. 
Lenta Ndjakou Bruno, Department of Organic Chemistry, University of Bielefeld, Germany.  
 
Table 3.1: List and codes of compounds tested in this study. 
Groups  Compounds  
MS 
MS1, MS2, MS3, MS4, MS6, MS8, MS9, 








RSH78( f )  
J 11 





































































































































































































































































































































































































































































































































































Figure 3.1: Structures of all experimental compounds. 
 
3.1.2 Assay method 
All the steady-state enzyme assays were performed at 25 °C using the modified 
spectrophotometric method of Feder and Schuck [135]. The method was modified such that a 
96-well microplate instead of single curette could be used, thereby increasing the through-put 
of the experiments. The principle of the assay is a “mix and measure”. Thermolysin is mixed 
with substrate FAGLA that is digested by thermolysin. The changes in absorbance due to the 
compound concentration by a spetctrophotometer which is proportional to the activity of 
thermolysin is detected. Thermolysin inhibition is measured by adding a fixed amount of 
thermolysin and a putative inhibitor to the well. Inhibitor blocks the activity of thermolysin. 
Therefore less substrate will be degraded, which reduces the signal detected by the 
spectrophotometer. The percentage of inhibition is calculated by the equation (3.1). 
For all assays, the concentrations of enzyme and substrate were 50 nM and 1.0 mM, 
respectively (the concentration in M). The thermolysin activity was determined by following 
the decrease in absorption at 346 nm due to the enzymatic hydrolysis of the substrate FAGLA. 
Three times crystallized thermolysin was obtained from a commercial supplier (Novabiochem, 
Germany) and used without purification. Stock solutions of Tris (50 mM), NaBr (2.5 M), and 
CaCl2 (10 mM), pH 7.0 were prepared and stored at 4 °C. A stock solution of FAGLA was 
prepared in DMF (dimethyl formamide), and diluted with buffer to a final concentration of 
0.1 M Tris, 0.1 M NaBr, and 2.5 mM CaCl2, pH 7.0 (final concentration of DMF, 2.5%). The 
enzyme and compounds were incubated for 15 min at 25 °C in a temperature-regulated 96-
 33
well microplate, and then the FAGLA solution was added to give a substrate concentration of 
1.0 mM. Initial velocities for <10% reaction were determined  [136, 137].  
These were in duplicate at three different concentrations (0.5, 0.05, and 0.005 mM) of 
all experimental compounds to get a view of the inhibition pattern. For compounds found to 














S ………….……………………………….…...…… (3.1) 
Where S and B stand for absorbance of experimental samples and blank. 
3.2 Docking calculation using ICM 
Three groups of ligand (25 ligands from literatures, 15 from MS compounds and 13 
from RS compounds) were docked to target protein. The regular docking methodology was 
used during the first time docking of 25 ligands from literature and initial docking of all 15 
ligands of MS group (Table 3.1). A modified method was applied in the docking of 13 ligands 
from R group, second time docking of 25 ligands form literature and docking of 2 MS 
compounds.   
3.2.1 Preparation of ligands before docking  
All the docking calculations of thermolysin inhibitors were performed using the 
ICM™ [97] docking module. First, the 2D structures of the literature retrieved inhibitors were 
drawn using the CS-ChemOffice (www.chembridgesoft.com) and converted to 3D using 
Discovery Studio (www.accelrys.com) and saved in PDB format.  
The X-ray coordinates of inhibitors that have been crystallized with thermolysin were 
extracted directly from the PDB file and energetically minimized using ICM. Then ligands 
were examined for bond order and protonation state.  
All carboxylic acids were deprotonated, tertiary amines were positively charged, 
phosphonates were partially deprotonated. Merck molecular force field (MMFF) [138] partial 
charges were assigned to the ligands.  
In the modified docking method, the structures were written out as mol table files from 
CS-Chemoffice ready for docking. Without manually preparations indispensable in the case 
of PDB structures, ligand structures from mol file can be automatically treated with all 
necessary optimizing processes on the fly after running docking simulations.  
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Based on structure similarity to ligands in X-ray complexes with thermolysin, the 25 
ligands were rearranged into 7 sub-groups (Table 3.2). The structure of th 25 ligands are 
shown in Figure 3.2. 
 
Table 3.2: Seven groups of 25 ligands from the literature. 
Group No. Ligand number 
X-ray structure within 
the group 
Group 1 6, 7, 8 ,10,11 1qf1 
Group 2 3, 4, 9 1qf2 
Group 3 5 1qf0 
Group 4 12,13 1os0 
Group 5 1,18 1y3g 
Group 6 
2, 14, 15, 16, 17, 19, 
20, 21 
5tmn,6tmn 


































































































































































































































































Figure 3.2: Structure lists of 25 thermolysin ligands from the literature. The PDB code is given for those 
obtained from X-ray complexes with thermolysin. 
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3.2.2 Preparation of the target protein 
In the meantime thermolysin (Target PDB code 1gxw) was prepared for the docking 
calculations with ICM. The retrieved 1gxw file from Brookhaven Protein databank (PDB, 
www.rcsb.org/pdb) was converted to ICM-object. 2266 missing hydrogens were added, and 
79 polar hydrogens were optimized. Metal ions were preserved, while crystallographic waters 
were deleted. This was followed by a local minimization to relieve potential bad contacts. 
During the first docking of the 25 ligands known from the literature and initial docking of MS 
compounds, the 3D space for docking was specified to include the entire binding pocket of 
the target (Figure 3.3). Zn was used as a core. All amino acids within 5 Å from the core were 
included in the 3D space of the pocket. A modified docking method was used for the other 
dockings. In this approach the ICM pocket finder module was used to determine the binding 
pocket, such that enough residues were included for obtaining correct receptor-ligand 
interactions. The measured volume of binding pocket for this method was 285.9 cubic 
angstroms, and radius 4.087 angstroms. Amino acids surrounding binding pocket were 
Asn112, Trp115, Gly117, Phe130, Leu133, Val139, His142, Glu143, His146, Asp150, 
Tyr157, Glu166, Ile188, Leu202, Arg203 and His231. The grid map was adjusted manually 
for all docking, and five potential maps (electrostatic, hydrogen bond, hydrophobic, van der 
Waals attractive and repulsive) were calculated for the receptor. 
 
 
Figure 3.3: The binding pocket of thermolysin (PDB: 1gxw). 
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3.2.3 Docking process 
Regular docking method is usually docking of one ligand at a time. To speed up the 
docking process, the modified method was using the ‘batch docking’ approach. Batch docking 
utilizes the ligands that are assembled as mol tables in one ‘sdf’ file. Instead of docking each 
ligand separately, the docking of multiple ligands can be done in one run and the results are 
displayed in an output file. It is ideal for large-scale docking jobs. Monte Carlo (MC) [139] 
docking runs were then performed. Based on our experiences from the regular docking of 25 
ligands from literature and 15 MS compounds, we performed 5 runs of docking for the rest of 
the ligands using the modified batch docking method. All dockings by the modified method 
were using the same grid maps. ICM stochastic global optimization algorithm attempts to find 
the global minimum of the energy function which includes five grid potentials describing 
interaction of the ligand. A torsional or positional conformation change, followed by local 
minimization, was performed at each step. During this process a stack of alternative low 
energy conformations was saved. The docked solutions (stacks) were checked visually. 
Multiple stack conformations were chosen based on their docking energies, and pose 
similarities to crystal structures.  
The ligands those have been through 5 runs of docking were analyzed differently. First, 
the best poses of each of 5 runs were saved based on docking energy, and similarity to x-ray 
structures, and then their docking energies were averaged. The one with a docking energy 
closest to the average value was chosen as reference which was sequentially used to calculate 
RMSD to remaining best poses (one from each run). Then a selection was done between the 
reference conformation and the one closest in RMSD, and the best conformation for each 
compound was finally used for calculation of their binding energies using the ICM script 
(briefly described in the following ‘Calculation’ section). 
Each docking process gave multiple conformations depending on the number of 
flexible side chains. The final conformation was chosen based on several points, like docking 
energy, hydrogen bonding, interactions with Zn, and interaction with the HEXXH motif.  
 
3.2.4 Calculation of the free energy of binding 
In the regular docking method, the free energies of binding (Cal.ΔG) between the 
protein and ligand was calculated for all possible conformations in each stack file. It was used 
as one of the guidelines for determining the best docking poses. But, in the modified docking 
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method, Cal.ΔG was calculated only for the best poses and compared with the experimental 
free energies of binding (Exp.ΔG) which was calculated from the experimental Ki values 
using equation 3.2. 
 
ΔG = -RTlnKi…………………………………………………………………....... (3.2) 
 
Where R is the gas constant (0.00198 Kcal/mol) and T is the temperature in Kelvin (298 K). 
The calcBindingEnergy macro of ICM was used to calculate the free energy of binding. 
This approach evaluates the binding of each ligand to target protein by estimating the 
electrostatic, hydrophobic and entropic energy terms. The evaluation of binding energy has 
the following features: van der Waals/hydrogen bonding interaction is excluded since it has 
close magnitudes for protein-protein and for protein-solvent interactions; electrostatic free 
energy change is calculated by the REBEL method; side-chain entropy change is calculated 
by standard ICM entropic term based on exposed surface area of flexible side-chains; 
hydrophobic energy change is calculated using surface term. Generally, the free energies of 
binding (Cal.ΔG) between the protein and ligand was calculated using ICM script utilizing 
equations 3.3 and 3.4 [140]. 
 
ΔG = ΔGH + ΔGEL + ΔGS + C.……………………………………………………. (3.3) 
 
ΔG = ΔGH + ΔGCOUL +ΔGDESOLV + ΔGS + C.………………………………….…. (3.4) 
 
where ΔGH is the hydrophobic or cavity term, which accounts for the variation of 
water/non-water interface area, ΔGEL is the electrostatic term composed of coulombic 
(ΔGCOUL) interactions and desolvation (ΔGDESOLV) of partial charges transferred from an 
aqueous medium to a protein core environment, and ΔGS is the entropic term which results 
from the decrease in the conformational freedom of functional groups buried upon 
complexation; and finally C is a constant that accounts for the change of entropy of the 
system due to the decrease of free molecules concentration (cratic factor), and loss of 
rotational/translational degrees of freedom [140]. The energy unit is kcal/mol. 
 
 39
3.2.5 Plotting the interactions using LigPlot 
For easy interpretations of the interactions between the receptors and the compounds 
LigPlot [141] was used to generate 2D plots of the ligand-thermolysin complexes.  
 
4 Result 
4.1 Molecular modeling of 25 thermolysin ligands from the literature 
To assess the prediction of binding modes and affinity by ICM and to characterize the 
docking accuracy, several parameters were calculated using both regular (default) and 
modified docking methods. The first parameter was docking energy which stands for the total 
of all the terms, both energy (i.e. " van der Waals, 1-4 van der Waals, hydrogen bonding 
energy, electrostatic energy, torsion energy, hydrogen bonding energy, bond stretching energy, 
surface term " ) and penalty part (i.e. " distance restraints, tethers, multidimensional variable 
restraints " ) [97]. The second parameter was the calculated binding energy (Cal.ΔG) between 
the docked ligand and thermolysin. This value was calculated by using equation 3.3 and 3.4. 
The third parameter, experimental free energies of binding (Exp.ΔG) was calculated from the 
experimental Ki values using the equation 3.2. The last calculated parameter was static Root 
Mean Square Deviation (sRMSD) from X-ray crystallographic structures. In the present, 
sRMSD gives the RMSD between the binding modes of two selected chemical (hetero) 
molecules according to the optimal chemical match by superimposing target protein 
coordinates, sRMSD was calculated between ligand structure conformation of the best ranked 
docking pose and the corresponding crystallographic protein coordinates. In our analysis, to 
maintain simplicity and evaluate the usefulness and true predictive capability of all sets of 
ligands, we chose to focus on both docking energy, sRMSD and the position of the putative 
ZBG as the basis for selecting between top ranked poses. We were very much interested in 
whether we could repeatedly rely on these criteria as an indication of the binding mode 
prediction. We determined the negative log of the experimental Ki as pKi [142] value of  
ligands to compare with calculated ΔG of the docking poses. The flexibility of the docked 
ligand was defined by the number of rotatable bonds. The experimental 3D coordinates were 
available only for those ligands co-crystallized with thermolysin. The Cambridge structural 
database (CSD) [143] was searched for ligand structures of the 25 ligands in this part of the 
study, but  structures were found.  To avoid that parameters and optimizing algorithm could 
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induce deviation due to different chemical structure drawing program of small molecules, 
only 2D mol files were used when using the modified docking method. All the optimizing and 
converting of 2D to 3D approaches were done by the ICM environment. The structure of 25 
ligands are shown in Figure 3.2. 
 
4.1.1 Initial docking of 25 ligands 
The ligands were divided into 7 sub groups according to their structural similarity with 
ligand co-crystallized with thermolysin. All possible stack conformations for each ligand were 
screened by calculating ICM binding energy (Cal.ΔG). Based on the similarity to crystal 
structure complexes with thermolysin and to the similarity of the calculated binding energy, 
the best poses were chosen (2 to 3 for each ligand).  These poses were then subjected to 
further refinements and similar evaluating approachs were performed for the refined poses, 
and final poses were selected. Table 4.1 demonstrates the changing of binding energy before 
and after refinement of the best poses. The correlation between the Cal. ΔG and Exp. ΔG was 
calculated by regression analysis indicated no correlation at all (R2 = 0.1874). The reason for 
that may be the presence of diverse chemical moieties in their skeletons.  
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Ki (in M) pKi  
Exp. 
ΔG 
  1 -131.7 -10.90 -1095 -9.38 4.1× 10-8 7.4 -10.0 
  2 -82.0 -7.79 -1068 -11.29 1.0× 10-8 8.0 -10.9 
  3 -79.1 -7.44 -986.5 -11.57 2.0× 10-7 6.7 -9.1 
1QF2 4 -91.6 -7.53 -1042 -7.45 1.2× 10-6 5.9 -8.0 
1QF0 5 -102.4 -6.08 -1067 -8.84 4.2× 10-8 7.4 -10.0 
1QF1 6 -76.7 -10.66 -1058 -7.83 4.8× 10-8 7.3 -9.9 
  7 -86.1 -10.58 -1072 -6.19 1.9× 10-8 7.7 -10.5 
  8 -76.1 -7.97 -1066 -4.70 1.0× 10-6 6.0 -8.2 
  9 -87.0 -8.05 -1052 -9.46 1.6× 10-6 5.8 -7.9 
  10 -79.6 -5.60 -1031 -5.08 1.6× 10-6 5.8 -7.9 
  11 -64.2 -3.87 -1046 -5.62 3.5× 10-7 6.5 -8.8 
1OS0 12 -112.2 -8.88 -1118 -13.74 9.3× 10-7 6.0 -8.2 
  13 -105.8 -7.55 -1116 -8.43 7.8× 10-7 6.1 -8.3 
  14 -136.8 -9.38 -1106 -13.05 2.6× 10-8 7.6 -10.3 
  15 -122.9 -7.57 -1073 -8.83 4.5× 10-8 7.4 -10.0 
  16 -127.3 -8.78 -1015 -9.59 6.8× 10-11 10.2 -13.8 
  17 -106.9 -9.78 -1069 -7.70 9.1× 10-9 8.0 -10.8 
1Y3G 18 -118.3 -10.31 -1082 -9.65 4.1× 10-8 7.4 -10.1 
  19 -109.4 -8.27 -1029 -6.72 1.0× 10-8 8.0 -10.9 
5TMN 20 -120.3 -6.31 -1090 -12.02 2.0× 10-7 8.0 -10.9 
6TMN 21 -123.9 -2.52 -1072 -3.94 1.2× 10-6 2.1 -2.8 
  22 -134.8 -10.99 -1119 -11.72 4.2× 10-8 7.1 -9.6 
  23 -99.7 -7.87 -976.2 -6.20 4.8× 10-8 6.3 -8.5 
  24 -72.4 -5.77 -1073 -7.34 1.9× 10-8 5.7 -7.7 






4.1.2 Re-docking of 8 ligands from X-ray structure complexes 
The ligands known from X-ray structure complexes of thermolysin were re-docked 
using two approaches. Glu143 in the TLN typically interacts with acceptor oxygen of bound 
ligand and most probably is in a protonated form. This residue therefore needs to be 
protonated, during docking as may His231, which forms a salt bridge with Asp 226 and 
typically places its second ring nitrogen atom within 3 Å of a second zinc bound oxygen of a 
carboxylate or phosphonate ligand [101] [144]. So, in one of the two docking approaches, 
Glu143 was protonated on OE2 position, while His142 and His146 were protonated on δ-N 
position. In the other re-docking approach, Glu143 was deprotonated while His142 and 
His146 were still protonated. A set of 8 ligands known from the thermolysin-inhibitor X-ray 
crystal structures were docked into two scenarios (un-protonated Glu143 and protonated 
Glu143).The binding pocket was assigned by ICMpocket finder algorithm [4]. Each of the 8 
ligand-thermolysin complexes was docked in 5 runs. The best poses were selected based on 
RMSD to original crystal structrures (Table 4.4 and 4.5). Docking energy was averaged over 
the 5 (Table 4.2 and 4.3). To make the comparing more objective, chart illustration were made 
for both energy value and RMSD (Figure 4.1, 4.2, 4.3 and 4.4). The general trend between the 
ligand flexibility and docking accuracy were analyzed.  
 
Table 4.2: Docking energy (kcal/mol) after docking into thermolysin with charged Glu143. The ligands were 
also charged.  
















 1QF2   8 -91.6 -89.9 -85.8 -90.2 -75.4 -83.7 -85.0 
 1THL   12 -112.9 -110.8 -103.6 -111.5 -100.1 -106.0 -106.4 
 1QF0   13 -102.4 -97.1 -91.6 -94.1 -94.1 -97.1 -94.8 
 1OS0   13 -112.2 -109.1 -104.5 -99.9 -99.3 -102.7 -103.1 
 1QF1   13 -76.7 -87.6 -88.0 -77.8 -88.3 -89.8 -86.3 
 5TMN   16 -120.3 -116.1 -94.1 -107.6 -100.7 -96.0 -102.9 
 6TMN   16 -123.9 -105.9 -92.7 -93.5 -100.0 -113.5 -101.1 
 1Y3G   16 -118.3 -105.8 -99.0 -110.6 -108.3 -119.3 -108.6 
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Table 4.3: Docking energy (kcal/mol) after docking into thermolysin with neutral Glu143 and charged ligands. 
















 1QF2   8 -91.6 -81.2 -81.6 -98.3 -87.1 -83.9 -86.4 
 1THL   12 -112.9 -94.2 -113.2 -101.6 -78.8 -107.6 -99.1 
 1QF0   13 -102.4 -98.6 -98.4 -108.5 -104.8 -104.7 -103.0 
 1OS0   13 -112.2 -105.0 -112.1 -111.8 -110.0 -105.2 -108.8 
 1QF1   13 -76.7 -83.2 -93.2 -86.8 -88.7 -89.0 -88.2 
 5TMN   16 -120.3 -105.3 -118.0 -104.7 -109.4 -105.5 -108.6 
 6TMN   16 -123.9 -109.5 -107.9 -108.0 -109.3 -99.9 -106.9 

















































































Figure 4.2: Chart illustration of docking energy values (kcal/mol) with neutral Glu143 receptor. 
 
Table 4.4: Corresponding sRMSD values relative to the x-ray structure with charged Glu143 and charged ligand. 















1QF2 8 6.29 1.59 2.29 5.41 4.32 6.54 4.03 
1THL 12 5.91 0.71 3.71 4.00 1.66 2.47 2.51 
1QF0 13 2.32 3.15 2.52 1.97 2.47 2.81 2.58 
1OS0 13 1.65 1.15 1.41 2.24 2.23 3.00 2.01 
1QF1 13 4.96 0.91 1.04 1.69 1.03 1.60 1.25 
5TMN 16 2.61 2.64 2.95 2.09 2.23 1.74 2.33 
6TMN 16 2.64 2.50 1.78 3.34 2.21 4.61 2.89 
1Y3G 16 4.81 2.79 2.23 1.96 1.90 1.52 2.08 
 
Table 4.5: Corresponding sRMSD values relative to the x-ray structure with neutral Glu143 and charged ligand.  















 1QF2   8 6.29 0.55 2.15 2.44 3.27 3.27 2.33 
 1THL   12 5.91 1.68 2.68 2.48 3.12 1.31 2.25 
 1QF0   13 2.32 1.39 2.94 1.70 2.22 2.49 2.15 
 1OS0   13 1.65 1.58 1.40 1.39 1.39 1.60 1.47 
 1QF1   13 4.96 1.47 2.71 0.97 0.96 1.05 1.43 
 5TMN   16 2.61 2.18 2.38 2.75 2.35 2.31 2.39 
 6TMN   16 2.64 4.77 2.20 4.87 4.52 2.74 3.82 




























d Rotatable bond 



































d Rotatable bond 








Figure 4.4: Chart illustration of sRMSD values with neutral Glu143 receptor. 
 
Re-docking of the 8 ligands with two different scenarios (charged or neutral Glu143) 
indicated that Glu143 most probably should be in a neutral form. The docking energies did 




4.1.3 Re-docking of the remaining 17 compounds of the 25 ligands  
Inspired by the relatively better docking accuracy compared with initial docking for 
the 8 ligands (most similar with x-ray crystal structures) using neutral Glu143, the rest of 17 
ligands were re-docked with similar grid maps and settings. The best poses were detected as 
described in the method part. The necessity of doing this was based on the fact that target 
protein and ligand are in constant motion between different conformational states with almost 
similar energies. So, instead of targeting a single pose of a given ligand in thermolysin, we 
tried to look for the most populated alternatives from an ensemble of stack conformations. 
Only small deviations of the best poses were seen between the 5 docking runs, but the energy 
was varying for some of the ligands (Table 4.6 and 4.7). The final results of the 25 ligands are 
shown in one Table 4.8. 
 
Table 4.6: Highest scored docking energy values (kcal/mol) of the best pose in each of the 5 docking runs for the 
remaining 17 of the 25 ligands from the literature. Reference docking indicates the docking run with the docking 
energy of the best scored pose closet to the average of the best scored poses. 
















1 16 -127.1 -121.7 -128.3 -125.7 -120.8 4 -124.7 
2 15 -107.8 -107.5 -107.7 -105.9 -107.2 5 -107.2 
3 9 -68.3 -71.2 -68.7 -71.3 -71.2 5 -70.2 
7 11 -88.6 -87.2 -87.5 -91.4 -88.0 1 -88.5 
8 9 -70,9 -73,3 -71,6 -70,9 -67,9 4 -70,9 
9 6 -84 -79,9 -84 -82,3 -82.3 5 -82.5 
10 7 -60.7 -70.5 -70.8 -60.7 -71.4 2 -66.8 
11 6 -65.4 -65.6 -65.3 -65.6 -65.6 2 -65.5 
13 11 -99.5 -97.1 -96.5 -97.3 -96.6 4 -97.4 
14 16 -125.8 -123.8 -128.9 -127.4 -127.8 1 -126.7 
15 16 -119.5 -130.5 -124.6 -124.5 -133.8 3 -126.6 
16 16 -128.7 -126.1 -132.9 -130.9 -130.7 5 -129.9 
17 15 -107.2 -101.0 -104.3 -103.3 -107.2 3 -104.6 
19 16 -120.6 -119.0 -115.8 -121.5 -117.3 2 -118.8 
22 11 -124.9 -129.3 -136.1 -126.6 -127.6 5 -128.9 
23 14 -103.5 -102.5 -104.6 -105.3 -106.9 4 -104.6 
24 10 -83.0 -85.1 -82.5 -85.9 -84.3 2 -84.2 
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Table 4.7: sRMSD values of 5 runs for the remaining 17 of 25 compounds. This sRMSD was calculated between 
the reference docking run and the remaining best scored docking runs. These values indicate the popularity of 
the reference docking pose within the 5 runs (the lower of this sRMSD values, the more popular of the reference 
docking poses).  
















1 16 3.39 3 2.79 / 3.91 4 3.27 
2 15 2.27 0.09 0.67 1.99 / 5 1.25 
3 9 0.16 0.01 0.21 0.02 / 5 0.1 
7 11 / 2.8 1.47 5.78 0.46 1 2.63 
8 9 0.02 1.78 1.31 / 2.2 4 1.33 
9 6 1.81 3.42 1.82 0.01 / 5 1.77 
10 7 2.02 / 2.02 0.13 0 2 1.04 
11 6 0.05 / 0.06 0.01 0.01 2 0.03 
13 11 2.43 2.36 2.06 / 1.19 4 2.01 
14 16 / 1.87 1.73 1.15 1.12 1 1.47 
15 16 1.83 4.07 / 0.81 2.27 3 2.24 
16 16 0.13 3.14 2.98 1.21 / 5 1.87 
17 15 2.17 1.21 / 1.96 1.68 3 1.76 
19 16 1.5 / 1.89 1.53 2.85 2 1.94 
22 11 2.19 2.97 2.78 3.08 / 5 2.76 
23 14 2.45 1.91 2.76 / 3.11 4 2.56 
24 10 1.29 / 2.53 2.24 2.03 2 2.02 
 
4.1.4 Final result of the docking of 25 ligands 
The final correlation between the Cal. ΔG and Exp. ΔG was calculated for regression 
analysis. The result showed that, the experimental and predicted binding energies (shown in 
Table 4.8) of the molecules were not significantly correlated (R2 = 0.56, p = 0.001), but was 
improved compared with the initial docking (Table 4.1). Diversified chemical moieties may 
still contribute to the un-ideal R2 values, but modified docking method may be the reason for 








Table 4.8: Ultimate poses and corresponding values for 25 compounds. 









  1 16 4.1×10
-8 [137] 7.4 -125.7 
  2 15 1.0×10
-8 [137] 8.0 -107.5 
  3 9 2.0×10
-7 [145] 6.7 -71.2 
1QF2 4 8 1.2×10
-6 [145] 5.9 -81.2 
1QF0 5 13 4.2×10
-8 [145] 7.4 -108.5 
1QF1 6 13 4.8×10
-8 [145] 7.3 -88.7 
  7 11 1.9×10
-8 [145] 7.7 -88.6 
  8 9 1.0×10
-6 [145] 6.0 -70.9 
  9 6 1.6×10
-6 [145] 5.8 -82.3 
  10 7 1.6×10
-6 [145] 5.8 -70.5 
  11 6 3.5×10
-7 [145] 6.5 -65.6 
1OS0 12 13 9.3×10
-7 [146] 6.0 -111.8 
  13 11 7.8×10
-7 [146] 6.1 -97.3 
  14 16 2.6×10
-8 [146] 7.6 -128.9 
  15 16 4.5×10
-8 [147] 7.4 -124.6 
  16 16 6.8×10
-11 [147] 10.2 -130.7 
  17 15 9.1×10
-9 [148] 8.0 -104.3 
1Y3G 18 16 4.0×10
-8 [14] 7.4 -119.0 
  19 16 1.0×10
-8 [14] 8.0 -119.0 
5TMN 20 16 9.1×10
-9 [14] 8.0 -118.0 
6TMN 21 16 9.0×10
-3 [14] 2.1 -107.9 
  22 11 8.0×10
-8 [52] 7.1 -127.6 
  23 14 5.6×10
-7 [52] 6.3 -105.3 
  24 10 2.2×10
-6 [52] 5.7 -85.1 
1THL 25 12 3.8×10
-7 [52] 6.4 -94.2 
 
The major drawback of hydrogen bond calculator by the LigPlot program is that it was 
designed for computing hydrogen bonds between protein side chains. Therefore LigPlot does 
not plot hydrogen bonds between metal ion and ligand. Manual inspections of the complexes 
in Table 4.8 were therefore needed to detect zinc interactions. Hydrogen bonding and zinc 
interactions of re-docked 25 ligands in Table 4.9 are shown schematically in the following 
figures.  
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For compound 1, all the detailed interactions are shown in Figure 4.5.1 and 4.5.2. The 
atoms C1, C7 and C9 of compound 1 showed hydrophobic interactions with His231. The 
atoms C4 and C6 interacted with Asn112 (CG), Phe130 and Leu202; C10 and C11 interacted 
with Phe114; C12 interacted with Tyr157 and Trp115 (CD1); C14 interacted with Asn116, 
Tyr157 and Trp115 (CD1); C16 interacted with Asn116; C17 interacted with Phe114 and 
Asn116; C19 and C22 interacted with His142 and Leu202. 
 
 
Figure 4.5.1: Schematic diagram of the interactions of compound 1 within the active site of thermolysin 
(Target PDB code 1gxw). The schematic 2D interaction plot between the thermolysin active site and compound 
1 was produced using the program LigPlot [141]. Labels of different bond type, hydrophobic residues and 
corresponding atoms involved in hydrophobic contact (s) interpreted in this figure apply to the whole LigPlot 
schemes in this study.   
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Figure 4.5.2: Stereo-chemical relationship between compound 1 and active site of thermolysin. Binding pocket is 
shown in transparent mode. Amino acids are corresponding to Ligplot of compound 1. 
 
The detailed interactions of compound 2 are shown in Figure 4.6.1 and 4.6.2. For 
compound 2, atoms C3, C13, C14, and C15 showed hydrophobic interactions with His231, 
while C5 and C8 interacted with His142; C11 interacted with Phe130; C17 and C18 interacted 
with Tyr157 and His146 (CG, CD2), and C19 and C20 interacted with Tyr157 only. 
 
Figure 4.6.1: Schematic diagram of the interactions of compound 2 with the active site of thermolysin (Target 
PDB code 1gxw).  
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Figure 4.6.2: Corresponding (to Figure 4.6.1) stereoview of compound 2 at the active site of thermolysin.   
 
The detailed interactions of compound 3 are shown in Figure 4.7. In case of compound 
3, S1 showed hydrophobic interactions with His231 (CD2); C4 also showed hydrophobic 
interactions with His231 but with other atoms (CG, CB, and CD2) of the same residue, C9 
also interacted with His231 (atoms CD2, CD, and CB). C8 interacted with Asn112 (CG); C13 
interacted with Leu133 and Phe130; C14 and C15 interacted with Leu133, Phe130, Val139 
and Leu202; C16 interacted with Val139 and Leu202; and C17 interacted with Leu202. 
 
Figure 4.7: Schematic diagram of the interactions of compound 3 with the active site of  thermolysin (Target 
PDB code 1gxw). 
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The detailed interactions between compound 4 and thermolysin are shown in Figure 
4.8. For compound 4, S1 showed hydrophobic interactions with His231; C4 interacted with 
Leu133, Phe130 and Val139; C5 interacted with Leu202; C6 and C8 interacted with Phe130, 
Leu133, Val139 and Leu202; C7 interacted with Leu133, Val139, Leu202 and His231; C9 
interacted with His231 and Leu202; atom C10 interacted with Asn112 (CG); C13 and C14 
interacted with His231 and atoms C17 and 19 interacted with Leu202 and His231. 
 
Figure 4.8: Schematic diagram of the interactions of compound 4 with the active site of  thermolysin (Target 
PDB code 1gxw).   
 
LigPlot and stereoscopic representations of compound 5 are shown in Figure 4.9.1 and 
4.9.2. For compound 5 atom S1 showed hydrophobic interactions with Phe114 and His146. 
C1, C3, C5, C7, and C8 interacted with Phe114; C4 interacted with Asn112 (CG); C15 
interacted with Leu133, Phe130, Leu202 and Ile188; C16 and C17 interacted with Leu202, 
Val139, and Ile188. C17 also interacted with Leu133. C13, C22 and C23 interacted with 
Phe130, Leu133 and Leu202. C19 and C27 interacted with His231 and C19 also interacted 
with Asn112 (CG); and C26 interacted with Phe130. The active site metal ion Zn showed 
ligand bonding (purple line in Figure 4.9.1) with O1 atom of compound 5. 
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Figure 4.9.1: Schematic diagram of the interactions of compound 5 with the active site of  thermolysin (Target 
PDB code 1gxw).   
 
Figure 4.9.2: Corresponding (to Figure 4.9.1) balls and sticks view of compound 5 at the active site of 
thermolysin.   
 
Figure 4.10.1 and 4.10.2 show the detailed interaction of compound 6 with 
thermolysin. In this compound, atoms C1, 4 and 5 showed hydrophobic interactions with 
Phe114. C11 and C13 interacted with Phe130, Leu133, Val139 and Leu202; C14 interacted 
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with Val139, Leu133 and Ile188; C15 interacted with Phe130, Leu133, Val139, Ile188 and 
Leu202; C19 interacted with His231. 
 
Figure 4.10.1: Schematic diagram of the interactions of compound 6 with the active site of thermolysin (Target 
PDB code 1gxw).   
 
Figure 4.10.2: Corresponding (to Figure 4.10.1) stereoview of compound 6 at the active site of thermolysin.   
 
For compound 7, atoms S1, C20 and C21 showed hydrophobic interactions with 
Trp115, Phe114, and Glu166, but C21 did not show interaction with Glu166 (Figure 4.11.1 
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and 4.11.2). C3 interacted with His231; C4 interacted with Asn112 (CG) and C8 interacted 
with Leu202; C9 and C10 interacted with Leu202, Ile188 and Val139; C10 also interacted 
with His142 (CB); C11 and C12 interacted with His142 (CD2, CG, CB) and Val139; while 
C15, C16, C17 and C18 interacted with Phe114. 
 
Figure 4.11.1: Molecular interactions of compound 7 with the active site of thermolysin (Target PDB code 
1gxw).  
 
Figure 4.11.2: Corresponding (to Figure 4.11.1) stereoview of compound 7 at the active site binding pocket of 
thermolysin.   
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The detailed interactions of compound 8 with thermolysin are shown in Figure 4.12. 
Atom S1 of the ligand showed hydrophobic interactions with Phe114 of thermolysin, and C3 
interacted with His231. C10 and C11 interacted with Phe130, Val139, Leu133 and Leu202. 
C12 interacted with Phe130, Val139, Leu133, Leu202 and Ile188. C13 interacted with Val139 
and Ile188 residues of the active site of thermolysin. 
 
Figure 4.12: Molecular interactions of compound 8 with the active site of thermolysin (Target PDB code 1gxw). 
 
For compound 9 (Figure 4.13), atom S1 showed hydrophobic interaction with His231 
(CD2) residue, while C11 had hydrophobic interaction with the same residue but with 
different atoms (CD2, CG and CB) of the residue. C14 also interacted with His231, but with 
atoms CD2 and CG. Atom C16 interacted with His142. C18 and C19 interacted with Val139 
and Leu202. C20 interacted with Val139, Leu202 and Phe130, and C21 interacted with 
Phe130, Val139, Leu133 and Leu202. 
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Figure 4.13: Molecular interactions of compound 9 with the active site of thermolysin (Target PDB code 1gxw). 
 
Figure 4.14 shows that S1 of compound 10 had hydrophobic interactions with His142, 
His146, His231 and Glu143 (long distant interaction). These residues are mostly the catalytic 
residues of the active site of thermolysin and the hydrophobic interactions with S1 seem 
important for the binding of the ligand within the active site. C3 also showed hydrophobic 
interactions with His231 and Leu202. C5 interacted with His231; C6 with His142 and His146; 
C8 with Leu202 and Ile188; C9 with Val139, Leu202, Ile188 and Leu133; atom C10 
interacted with Phe130, Leu202, Val139, Leu133 and Ile188. C11 interacted with Phe130, 
Leu133, Val139 and Leu202. 
 58
 
Figure 4.14: Molecular interactions of compound 10 with the active site of thermolysin (Target PDB code 1gxw). 
 
For compound 11, all the detailed interactions with thermolysin are shown in Figure 
4.15. Atom S1 showed hydrophobic interactions with His231 and His142 (CD2). Atom C3 
interacted with Asn112 (CG); C6 with His142 (CD2); C8 and C9 interacted with Ile188, 
Leu202 and Val139, while C10 and C11 interacted with Leu202, Val139, Leu133 and Phe130. 
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Figure 4.15: Molecular interactions of compound 11 with the active site of thermolysin (Target PDB code 1gxw). 
 
Figure 4.16 is showing the LigPlot of compound 12 in the active site of thermolysin. 
Atoms C1, C3, C4, C5, C6, C7 and C8 of 12 showed hydrophobic interactions with Phe114 of 
thermolysin. Atoms C13, C15 and C17 interacted with Leu133, Leu202 Val139 and Phe130. 
C16 interacted with Leu133, Leu202 and Val139. C18 interacted with Leu202 and His231 
(CD2). C21 interacted with Asn112 (CG) and C24 interacted with Leu202, Phe130 and 
His231 (CD2).  
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Figure 4.16: Molecular interactions of compound 12 with the active site of thermolysin (Target PDB code 1gxw). 
 
The detailed interactions of compound 13 are shown in Figure 4.17. For this 
compound atoms C1, C2, C3, C4, C6 and C7 had hydrophobic interactions with Tyr157, 
Phe114 and His146. C9 showed hydrophobic interactions with His231 (CD2). C14 and C15 
interacted with Leu202 and Val139. C16 interacted with Leu202, His142, Val139 and Ile188; 
atom C17 interacted with Ile188; C18 interacted with Leu202, His142 and Val139; and C21 
interacted with Asn112 (CG). In this complex, hydrogen bond between Asp226 and His231 
(2.48 and 2.76 Å) are important for the active site architecture.  
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Figure 4.17: Molecular interactions of compound 13 with the active site of thermolysin (Target PDB code 1gxw). 
 
The detailed interactions of compound 14 are shown in Figure 4.18.1 and 4.18.2. For 
compound 14 atoms C2 and C3 showed hydrophobic interactions with Asn112 (CG). Atom 
C4 interacted with Phe114 and Trp115. C13, C14 and C15 interacted with Trp115, Asn116, 
Gly117 and Tyr157. C16 interacted with Phe114, Trp115 Asn116 and Tyr157; C17 interacted 
with His142 and His231; C19 interacted with His142 and Leu202. C21 interacted with 
Leu202, His142 and Ile188. C22 and C23 interacted with Leu202, His142, Ile188 and Val139; 
and C24 interacted with Leu202, Leu133 and Val139. 
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Figure 4.18.1: Molecular interactions of compound 14 with the active site of thermolysin (Target PDB code 
1gxw). 
 
Figure 4.18.2: Corresponding (to Figure 4.18.1) stereoscopic view of compound 14 at the active site of 
thermolysin.   
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Detailed interactions of compound 15 are shown in Figure 4.19.1 and 4.19.2. Atoms 
C2, C3 and C4 showed hydrophobic interactions with Asn112 (CG). C10, C11, C12, C13, 
C14, C15 and C16 interacted with Tyr157. C18 and C21 interacted with His142.  
 




Figure 4.19.2: Corresponding (to Figure 4.19.1) stereoscopic view of compound 15 at the active site of 
thermolysin.   
 
Figure 4.20.1 and 4.20.2 show the molecular interactions of compound 16 at the active 
site of thermolysin. For compound 16 atoms C2 and C3 exhibited hydrophobic interactions 
with Asn112 (CG) and C4 interacted with Phe114. Atoms C10, C12, C14 and C15 interacted 
with Tyr157. C14 and C15 also interacted with Asn116. C18 and C21 interacted with His142.  
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Figure 4.20.1: Molecular interactions of the compound 16, the most potent inhibitor (Ki = 6.8×10-11 mM) of the 
25 ligands, within the active site of thermolysin (Target PDB code 1gxw).  
 
Figure 4.20.2: Corresponding (to Figure 4.20.1) stereoscopic view of compound 16 at the active site binding 
pocket of thermolysin.   
 
For compound 17, all detailed interactions are shown in Figure 4.21.1 and 4.21.2. For 
this compound, atoms C1, C6, C7 and C8 demonstrated hydrophobic interactions with 
Leu202; C7 and C8 also interacted with Val139 and Ile188. Atom C2 interacted with the 
His231 (CG, CD2 and CE1) residue. Both C5 and C8 interacted with the atoms of His142 
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(CG, CD2, CB); C11, C12 and C13 interacted with Trp115 and C12 and 13 also interacted 
with Tyr157. Finally C17 and C18 interacted with His231 (CG, CE1 and CD2).  
 
Figure 4.21.1: Molecular interactions of compound 17 with the active site of thermolysin (Target PDB code 
1gxw). 
 
Figure 4.21.2: Corresponding (to Figure 4.21.1) stereoscopic view of compound 17 at the active site binding 
pocket of thermolysin.   
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For compound 18, all detailed interactions are shown in Figure 4.22.1. and 4.22.2. 
Atoms C1 and C2 had hydrophobic interactions with His146 (CD2); C2 and 3 interacted with 
Tyr157. C8 and C19 interacted with Phe114 and His231 (CD2 and CG), respectively. Atoms 
C15, C16 and C17 showed interactions with Val139, Leu202, Leu133 and Phe130. C21 
interacted with Asn112 and C22 with Leu202 and Phe130. 
 




Figure 4.22.2: Corresponding (to Figure 4.22.1) stereoscopic view of compound 18 at the active site binding 
pocket of thermolysin.   
 
For compound 19, all the detailed interactions with thermolysin are shown in Figure 
4.23.1 and 4.23.2. Atom C1 revealed hydrophobic interaction with His231 (CE1). Atoms C7 
and C10 interacted with Leu202. C11 and 12 interacted with Leu202, Ile188 and Val139. 
Atom C11 also interacted with Asn112 (CG) and C12 also interacted with His142. Atom C13 




Figure 4.23.1: Molecular interactions of compound 19 with the active site of thermolysin (Target PDB code 
1gxw). 
 
Figure 4.23.2: Corresponding (to Figure 4.23.1) stereoscopic view of compound 19 at the active site binding 




For compound 20, all the detailed interactions are shown in Figure 4.24.1 and 4.24.2. 
Atoms C2 and C4 exhibited hydrophobic interactions with Tyr157 and His146. Atom C13 
interacted with Val139, Phe130 and Leu202; atoms C14 and 15 interacted with Val139 and 
Leu202; C14 also interacted with Leu133 and Phe130; and atoms C18 and C21 interacted 
with His231 (CE1, CG and CD2). 
 




Figure 4.24.2: Corresponding (to Figure 4.24.1) stereoscopic view of compound 20 at the active site binding 
pocket of thermolysin.   
 
Detailed interactions of compound 21 are shown in Figure 4.25. Atom C1 showed 
hydrophobic interactions with Tyr157, His146, Phe114 and Asn116. C2 interacted with 
Tyr157 and His146. C5 and C6 interacted with Phe114 and Asn116. C9 interacted with 
Phe114 and His146. C13 and C14 interacted with Leu202 and Phe130. C15 and C17 
interacted with His231 (CB and CG). C17 also interacted with Leu202, while C20 interacted 
with Asn112 (CG), Leu202 and Phe130. 
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Figure 4.25: Molecular interactions of compound 21 with the active site of thermolysin (Target PDB code 1gxw). 
 
Detailed interactions of compound 22 are shown in Figure 4.26.1 and 4.26.2. Atom C1 
exhibited hydrophobic interaction with Phe114, C3 with His231 (CE1), C4 interacted with 
Tyr157 and His146 (CD2), C5 with Tyr157 and Phe114, C6 interacted with Phe114 and 
His146 (CD2). C9 interacted with Leu202 and Phe130. C10 interacted with Val139, Leu133, 
Phe130, Leu202 and Asn112 (CG). C15 and C16 interacted with Leu202 and Phe130. C17, 




Figure 4.26.1: The molecular interactions of compound 22 with the active site of thermolysin (Target PDB code 
1gxw). 
 
Figure 4.26.2: Corresponding (to Figure 4.26.1) stereoscopic view of compound 22 at the active site binding 
pocket of thermolysin.   
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Detailed interactions of compound 23 are shown in Figure 4.27. For this compound 
atom C1 exhibited hydrophobic interactions with His146, His142 and Phe114. These 
interactions are very important as residues His146 and His142 are playing vital role as active 
site residue of thermolysin. C4, C5 and C6 interacted with Phe114 and His146. C8 and C9 
interacted with Tyr157 and His146. C16 and C17 interacted with His231 (CG and CD2). C12 
interacted with His142. C24 and C25 interacted with Phe130. C24 also interacted with 
Asn111 (CB), and C26 interacted with Asn112 (CG). 
 
Figure 4.27: The molecular interactions of compound 23 with the active site of thermolysin (Target PDB code 
1gxw). 
 
For compound 24, all detailed interactions are shown in Figure 4.28. Atoms C5 and 
C19 had hydrophobic interaction with Asn112, and C19 also interacted with His146 (CD2). 
C8 interacted with His142, while C9, C10, C11 and C12 interacted with Leu202; C9, C11 and 
C12 also interacted with His231 (CB, CG and CD2), and C18 interacted with Phe114. 
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Figure 4.28: The molecular interactions of compound 24 with the active site of thermolysin (Target PDB code 
1gxw). 
 
For compound 25, all detailed interactions are shown in Figure 4.29.1 and 4.29.2. For 
this compound, atoms C3 and C11 had hydrophobic interactions with Asn112 (CG). C4, C5, 
C6, C7, C8 and C9 interacted all with Phe114. C13 and C14 interacted with Leu202; C14 also 
interacted with Phe130 and Asn112 (CG). C16 showed interaction with Leu133, C18 and 19 
with His231 (CE1), while C27 and C28 interacted with Leu202 and Phe130. 
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Figure 4.29: Molecular interactions of compound 25 with the active site of thermolysin (Target PDB code 1gxw). 
 
Figure 4.29.2: Corresponding (to Figure 4.29.1) stereoscopic view of compound 25 at the active site binding 
pocket of thermolysin. 
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Table 4.9: Docking Interactions of 25 thermolysin inhibitors from literature based on the second docking. 
Comp. Interactions with Zn Distance in Å 
H-Bond 






1 Zn-O4 (2.57) Zn-O5 (2.28) 
O6-Trp115(N 3.28) 
O2-His146(NE2 3.32) 
























6 Zn-O1 (2.05) 
O4-Asn112(ND2 2.70) 
S1-His146(NE2 3.18) 






8 Zn-O3 (2.10) 
O2-Arg203(NH2 3.14) 
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22 Zn-O2(2.51) Zn-O7(3.05) 
O10-Asn112(ND2 2.67) 
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24 Zn-O1(2.09) Zn-O2(2.29) 
O3-Arg203(NH2 3.08) 
O1-His231(NE2 3.19) 
O3-Arg203(NH1 2.66) 25 Zn-O1(2.37) Zn-O2(2.23) 
O5-Asn112(ND2 2.70) 
 
4.2 MS Compounds   
4.2.1 Experimental studies of MS compounds 
Thermolysin activity was assayed with the chromophoric substrate FAGLA by 
monitoring the decrease in absorbance at 346 nm due to the hydrolysis of the Gly-Leu bond 
[149]. The inhibition characteristics of MS compounds for thermolysin using FAGLA as the 
substrate, is given in Table 4.10.  Two (MS9 and MS12) out of 13 diterpenoid alkaloids were 
showed active, having IC50 values of 0.00991 and17.674 mM, respectively. Eight compounds 
were completely inactive, and three compounds showed very low activity and the IC50 value 
could not be detected. The inhibition of MS12 appears far poorer than MS9. M9 and M12 
were subjected to kinetic and other experimental as well as molecular modeling studies in 
order to predict their mode of binding at the active site of thermolysin. The kinetic studies are 










Table 4.10: Experimental result of MS compounds.  
Comp. IC50 (in mM) 
MS1 Low a  
MS2 IN b  
MS3 IN b  
MS4 IN b  
MS6 IN b  
MS8 IN b  
MS9 9.91x10 3−  
MS10 IN b  
MS11 IN b  
MS12 17.674 
MS13 Low a  
MS14 Low a  
MS15 IN b  
NOTES:  a due to the low activities the IC 50  values were not possible to calculate; 
b completely inactive.  
 
4.2.2 Docking of MS compounds 
Before experimental assay, all the ligands were docked to target protein using regular 
docking method. Due to lack of crystal structure as a guideline to evaluate the poses, only the 
highest scored conformation (best docking energy) was selected. Calculated ICM binding 
energy indicated varying degree of binding for all 13 ligands (Table 4.11), while experimental 
result implied only 2 real binders (MS09 and MS12).  The modified docking method used for 
















MS1 -3.2 -94.3 
MS2 -7.0 -118.5 
MS3 -6.2 -100.0 
MS4 -5.9 -78.9 
MS6 -5.8 -99.2 
MS8 -3.9 -79.5 
MS9 -3.6 -92.6 
 MS10 -3.3 -105.1 
 MS11 -5.2 -96.6 
 MS12 -5.1 -82.5 
 MS13 -7.4 -79.5 
 MS14 -5.0 -57.9 
 MS15 -4.5 -93.2 
 
 
Table 4.12: Docking energy value (kcal/mol) of top poses (the 1st pose in each round). Reference docking run 
stands for the best ranked pose in each of 5 runs with the docking energy closest to the average value. 






MS9 15 -108.3 -105.6 -107.8 -108.6 -108.9 1 -107.8 
MS12 6 -72.6 -72.6 -73.5 -71.2 -73.0 2 -72.6 
 
 
Table 4.13: sRMSD values of the best pose from each run relative to the top scored reference docking run. 





MS9 15 / 0.32 0.07 0.42 0.3 1 0.28 
MS12 6 4.53 / 2.98 4.46 0.67 2 3.16 
 
For compound MS9 (Figure 4.30.1 and 4.30.2), the O4 atom formed a hydrogen bond 
with the active site metal cation Zn at an atomic distance of 2.57 Å. The same atom also 
formed hydrogen bonding with the NE2 atom of His146, which is an important active site 
amino acid residue. The same compounds also had several hydrophobic interactions with 
different atoms. Atoms C7, C9, C10, and C12 showed hydrophobic interactions with Asn112 
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and Phe114. C14 interacted with Tyr157. C23, C24, C25, C26 and C35 had hydrophobic 
interactions with His231, another important active site residue. Atom C35 interacted with 
Val230, while C36 exhibited several hydrophobic interactions with Asn112, Phe114 and 
Asn116.  
 
Figure 4.30.1: Molecular interactions of the MS9 within the active site of thermolysin (Target PDB code 1gxw). 
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Figure 4.30.2: Corresponding (to Figure 4.30.1) stereoscopic view of compound MS9 at the active site binding 
pocket (grey transparent mode) of thermolysin.   
 
For compound MS12 (Figure 4.31.1 and 4.31.2), the two oxygen atoms O2 and O4 
formed hydrogen bonds with Zn at atomic distance of 2.98 and 2.42 Å, respectively. The 
hydrogen bond between O4 and Zn was similar but shorter than that of O4 of compound 
MS12. With zinc, O2 also formed hydrogen bonds with the NE2 and OE2 atoms of His146 
and Glu166, respectively. Their interatomic lengths were calculated using LigPlot and found 
to be 3.1 and 2.63 Å, respectively. Atoms C7, C8, C9, C10 and C17 showed hydrophobic 
interactions with Phe114; and atoms C11, 12, C13 and C14 interacted with His231. 
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Figure 4.31.1: Molecular interactions of the MS12 within the active site of thermolysin (Target PDB code 1gxw). 
Hydrogen bonding of Zn-O2 and Zn-O4 were overlapped in this figure.  
 
Figure 4.31.2: Corresponding (to Figure 4.31.1) stereoscopic view of compound MS12 at the active site binding 













( Distance, in 
Å) 
H-Bond (Atom no, 
Length, in Å) 
MS9 -107.8 Zn-O4 (2.57) O4-His146(NE2 3.07) 
Zn-O2 (2.98) O2-His146(NE2 3.10) 
MS12 -72.61 
Zn-O4 (2.42) O2-Glu166(OE2 2.63) 
 
4.3 R Compounds 
4.3.1 Experimental studies of R compounds 
The IC50 values of the R compounds for thermolysin using FAGLA as the substrate 
are given in Table 4.15. The studies indicated that 12 out of 39 compounds were active. Four 
compounds were completely inactive; 22 compounds showed low activities. The binding of 
RS17, RSH57 and RSH78 (f) appeared stronger than the rest of the active compounds. 
Enzyme kinetic studies were described in our manuscript [151]. 
 
Table 4.15: Experimental activity profiles (IC50) of R compounds. 
Comp. IC 50  (in mM) Comp. IC 50  (in mM) 
RK2-16 IN b  RSH30-d Low a  
RSH11 0,648 RS 25 Low a  
RS10 IN b  RSH-1 Low a  
RSH22(b) IN b  RSH 42 Low a  
RS17 1.1461x10 5−  RK1-4 Low a  
RK10(2) Low a  RSH77(c ) Low a  
RSH79(a) Low a  RSH28(b) Low a  
RSH78( f ) 1.25x10 3−  RSH 16 Low a  
J 11 Low a  RS 14 Low a  
RSH 10 4.002 RSH 41 12.743 
RS 12 Low a  RSH 23 Low a  
RSH 57 2.4774x10 4−  RSH78(g) Low a  
RS 7 Low a  RSH39(d) Low a  
RSH 66 Low a  RS-1 IN b  
RSH30d-2 Low a  J1 122.637 
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Table 4.15 Continued 
RK2-10 Low a  RM19 0.037862 
RS20(R ) Low a  RS3 0.042035 
RSH19(b) Low a  RSH12 1.8321 
RSH35-A 3.118 RSH44a 0.076851 
NOTES: a due to the low activities the IC50 values were not possible to calculate; 
b completely inactive. 
 
4.3.2 Docking studies of R compounds 
Only the R-compounds found to bind thermolysin in experimental studies were 
docked into thermolysin. The ligands were charged and Glu143 was neutral in the docking. A 
unique Quinazoline group distinguished R compounds from all the other ligands in this study 
(Figure 3.1). Different sources (PDB database, Cambridge structural database) were searched 
for potential crystal structure of the experimentally active R compounds, but structures were 
not found. Models of the compounds were therefore constructed using CSChemOffice. Lack 
of flexibility (most of them have only 1 to 2 rotatable bonds) made it less important to sort 
native geometries for the R compounds. In general feed batch docking with 2D structures (in 
SD file converted from mol file) and all necessary minimizations were performed by default 
settings. A modified docking approach and evaluation of the docking poses were performed 
as described previously (paragraph 3.2.2 and 3.2.3). The results are shown in Table 4.16 and 
4.17. Except RK1-4, all docked compounds showed negative binding free energies, indicating 
that a realistic binding scenario was generated (Table 4.18). However, the correlation between 
binding energies and IC50 was not linear, which indicates that the docked conformations are 














Table 4.16: Docking energy values (kcal/mol) of 5 runs for R compounds. Reference docking run stands for the 
best ranked pose in each of 5 runs with the docking energy closest to the average value. 






J1 4 -48.3 -47.5 -47.5 -48.3 -48.3 1 -48.0 
RK1_4 2 -49.2 -48.7 -48.1 -49.8 -48.1 2 -48.8 
RM19 1 -35.9 -36.2 -35.9 -36.1 -35.9 3 -36.0 
RS17 2 -49.3 -49.4 -49.3 -46.6 -46.6 3 -48.2 
RS3 4 -65.9 -66.1 -66.1 -65.9 -66.2 3 -66.1 
RSH10 3 -61.2 -57.5 -57.6 -57.5 -57.6 3 -58.3 
RSH11 3 -61.5 -56.1 -61.6 -61.6 -61.6 4 -60.5 
RSH12 2 -61.1 -60.7 -55.0 -54.7 -60.7 3 -58.4 
RSH35a 2 -51.8 -51.8 -51.8 -51.8 -51.8 5 -51.8 
RSH41 1 -48.5 -49.9 -48.6 -49.3 -47.8 3 -48.8 
RSH44a 2 -54.5 -53.4 -53.3 -54.4 -54.4 1 -54.0 
RSH57 1 -41.2 -41.2 -41.2 -41.1 -41.2 1 -41.2 
RSH78f 1 -51.2 -51.1 -51.1 -51.2 -51.1 3 -51.1 
 
 
Table 4.17: sRMSD between the best pose of reference docking run and the best poses of the other docking runs. 






J1 4 / 0.36 0.34 0.01 0.00 1 0.18 
RK1_4 2 1.21 / 0.05 0.19 0.05 2 0.38 
RM19 1 0.00 0.01 / 0.02 0.00 3 0.01 
RS17 2 0.00 0.00 / 0.26 0.26 3 0.13 
RS3 4 0.86 0.86 / 0.02 0.21 3 0.49 
RSH10 3 1.42 0.00 / 0.00 0.03 3 0.36 
RSH11 3 0.00 0.27 0.00 / 0.00 4 0.07 
RSH12 2 1.51 1.51 / 0.03 1.51 3 1.14 
RSH35a 2 0.02 0.00 0.00 0.00 / 5 0.00 
RSH41 1 0.01 0.19 / 1.38 1.47 3 0.76 
RSH44a 2 / 0.30 0.30 0.00 0.00 1 0.15 
RSH57 1 / 0.01 0.01 0.00 0.11 1 0.03 





Table 4.18: Final results of R compounds. 




Cal.ΔG IC50 (in mM) 
J1 4 -48.3 -1.8 122.637 
RK1-4 2 -48.7 1.0 low activity 
RM19 1 -36.2 -1.5 0.037862 
RS17 2 -49.3 -1.0 0.00001146 
RS3 4 -66.2 -3.9 0.042035 
RSH10 3 -57.6 -3.5 4.002 
RSH11 3 -61.6 -4.1 0.648 
RSH12 2 -55.0 -2.4 1.8321 
RSH35a 2 -51.8 -3.5 3.118 
RSH41 1 -48.6 -4.8 12.743 
RSH44a 2 -54.5 -3.7 0.076851 
RSH57 1 -41.2 -9.7 0.00024774 
RSH78f 1 -51.1 -2.8 0.00125 
 
The different interactions (docking energy, inter atomic interactions with Zn, 
hydrogen bondings and hydrophobic interaction) of thermolysin inhibitors are comparatively 
shown in Table 4.19. The hydrophobic interactions depicted on 2D LigPlot figures were 
confirmed by visually analysing the 3D structure complexes in ICM environment.    
All the detailed interactions of compound J1 are shown in Figure 4.32. The atom C2 
showed hydrophobic interaction with His142 (CD2). C5 interacted with Asn112. C7 and C8 
interacted with Leu202. C9 interacted with Asn112 and His231 (CE1). C10 interacted with 
Asn112. C13, C14 and C17 interacted with His231 (CE1).  C16 interacted with Phe114, while 
C18 interacted with Tyr157. 
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Figure 4.32: Schematic illustration of the interactions of J1 at the active site of thermolysin (Target PDB code 
1gxw). The schematic 2D interaction plot between thermolysin active site and the J1 was produced using the 
program LigPlot [141].  
 
For compound RK1-4, all detailed interactions are shown in Figure 4.33. Atom C1 
had hydrophobic interaction with Leu202, while atom C5 and C7 interacted with Asn112 




Figure 4.33: Schematic illustration of the interactions of RK1-4 with the active site of thermolysin (Target PDB 
code 1gxw). 
 
All detailed interactions of compound RM19 are shown in Figure 4.34. Atoms C1 and 
C8 had hydrophobic interaction with Leu202. C6 and C7 interacted with Asn112 (CG), while 
C9 interacted with His231. 
 
Figure 4.34: Schematic illustration of RM19 at the active site of thermolysin (Target PDB code 1gxw). 
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For RS3, all the detailed interactions with thermolysin are shown in Figure 4.35. C1 
and C8 had hydrophobic interaction with Leu202, while C2 and C3 interacted with His231. 
C6 and C7 interacted with Asn112 (CG). C16 interacted with Trp115, Tyr157 and His146. 
C17 and C18 interacted with Trp115 and Tyr157, and C19 interacted with Tyr157.  C21 and 
C22 interacted with Trp115 and Tyr157. 
 
Figure 4.35: Schematic illustration of the interactions of RS3 at the active site of thermolysin (Target PDB code 
1gxw). 
 
All detailed interactions of compound RS17 are shown in Figure 4.36.1 and 4.36.2. C1 
and C2 had hydrophobic interaction with Tyr157 and His146 (CG, CD2). C7 interacted with 




Figure 4.36.1: Schematic illustration of  RS17 at the active site of thermolysin (Target PDB code 1gxw). 
 
Figure 4.36.2: Corresponding (to Figure 4.36.1) stereoscopic view of compound RS17 at the active site binding 
pocket (grey transparent mode) of thermolysin.  
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All detailed interactions of compound RSH10 are shown in Figure 4.37. Atom C1 had 
hydrophobic interaction with Val139. C2 interacted with His142 (CG, CD2). C4 interacted 
with His142 (CD2). C8, C9 and C10 interacted with Tyr157, while C11 interacted with 
His146. C12, C16, C17 and C18 interacted with Asn112. C14 and C15 interacted with 
Leu202. C20 and C21 interacted with His231 (CE1). 
 
Figure 4.37: Schematic illustration of RSH10 in the active site of thermolysin (Target PDB code 1gxw). 
 
Figure 4.38 shows the detailed interactions of RSH11 with thermolysin. Atom C2 had 
hydrophobic interaction with His142 (CG, CD2), while C4 interacted with His142 (CD2). C5, 
C9 and C10 interacted with Asn112. C7 and C8 interacted with Leu202. C13 and C14 




Figure 4.38: Schematic illustration of RSH11 in the active site of thermolysin (Target PDB code 1gxw). 
 
Detailed interactions for RSH12 are shown in Figure 4.39. The figure shows that C2 
had hydrophobic interaction with His142 (CG, CD2). C4 interacted with His142 (CD2), and 
C5 interacted with Asn112. C6 interacted with Asn112 and His231, while C8 and C9 
interacted with Leu202. C13 and C14 interacted with Tyr157. C15 and C16 interacted with 
His146 and Tyr157. 
 
Figure 4.39: Schematic illustration of the RSH12 in the active site of thermolysin (Target PDB code 1gxw). 
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Detailed interactions for compound RSH35a are shown in Figure 4.40. The figure 
shows that atom C1 had hydrophobic interaction with His231 and Asn112. C2, C3, C4, C6 
and C7 interacted with His231. C8 interacted with Asn112, while C12, C13 and C14 
interacted with Tyr157. 
 
Figure 4.40: Schematic illustration of RSH35a at the active site of thermolysin (Target PDB code 1gxw). 
 
For compound RSH41, all detailed interactions are shown in Figure 4.41. The atoms 
C2, C3, C4, C5, C6 and C7 showed hydrophobic interaction with His231. C1 and C8 
interacted with Asn112, while C12 and 13 interacted with Tyr157. 
 97
 
Figure 4.41: Schematic illustration of RSH41 at the active site of thermolysin (Target PDB code 1gxw). 
 
For compound RSH44a, detailed interactions are shown in Figure 4.42. The figure 
shows that atoms S1, C11 and C18 had hydrophobic interaction with Phe114. C1, C2, C3 and 
C4 interacted with His231, while C5 interacted with Asn112 (CG). C6 interacted with Asn112 
(CG) and His231. C10 interacted with Asn112 (CG) and Phe114. C17 interacted with His146. 
 




All the detailed interactions of compound RSH57 are shown in Figure 4.43.1 and 
4.43.2. C2 had hydrophobic interaction with His142 (CG, CD2 and CE1). C3 interacted with 
His142 (CG, CD2), and C4 interacted with His142 (CG). C6 interacted with Asn112 (CG) 
and C7 interacted with His231 (CE1, CD2). C12 interacted with His146, Glu143 and Phe114, 
while C13 interacted with Tyr157 and His146. Atom O1 formed covalent bonds (purple line 
in Figure) with active site zinc ion and His142 (NE2).  
 
Figure 4.43.1: Schematic illustration of RSH57 at the active site of thermolysin (Target PDB code 1gxw). 
 
Figure 4.43.2: Corresponding (to Figure 4.43.1) stereoscopic view of compound RSH57 at the active site binding 
pocket (grey transparent mode) of thermolysin 
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For compound RSH78f, detailed interactions with thermolysin are shown in Figure 
4.44.1 and 4.44.2. C1 had hydrophobic interaction with Val139, and C2 interacted with 
His142 (CD2). C4 interacted with His231, while C6 and C7 interacted with Leu202. C8 
interacted with Leu202 and Val139. C10 interacted with His231.  
 
 
Figure 4.44.1: Schematic illustration of RSH78f at the active site of thermolysin (Target PDB code 1gxw). 
 
Figure 4.44.2: Corresponding (to Figure 4.44.1) stereoscopic view of compound RSH78f at the active site 
binding pocket (grey transparent mode) of thermolysin. 
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Distance in Å 
H-Bond (Atom no, 





N2-Asn112(ND2 2.90) RK1-4 Zn-O1(2.50) 
N3-His231(NE2 2.80) 
O1-His142(NE2 2.49) 
RM19 Zn-O1(2.37) Zn-N2(2.83) N3-Asn112(ND2 2.94) 
RS3 Zn-O1(2.23) N2-Asn112(ND2 2.82) 




RSH11 Zn-O1(2.25) O1-His142(NE2 2.47) 
RSH12 Zn-O1(2.27) O1-His142(NE2 2.56) 
N2-His146(NE2 2.77) 
RSH35a Zn-O1(2.50) Zn-N2(2.46)   
O1-His142(NE2 3.35) 
RSH41 Zn-O1(2.42) Zn-N2(2.53) N2-His146(NE2 3.17) 
N2-Asn112(ND2 2.84) 
RSH44a Zn-O1(2.62) Zn-N3(2.74)   
N3-His231(NE2 2.96) 
RSH57     
RSH78f Zn-O1(2.48) O1-His142(NE2 2.95) 
 
 
4.4 Experimental result of M compounds 
The IC50 values of another series of compound (M compounds) were also performed 
in this thesis. The inhibition characteristics of M compounds for thermolysin using FAGLA as 
the substrate, is given in Table 4.18. Two out of seven compounds were active. Compound 
MTA8 showed extraordinarily strong inhibition with an IC50 value of 4,411x10-11 mM.  Four 
compounds showed low active and one compound very low activity. The inhibition of 
MTA8AC appeared far poorer than that of MTA8. Due to shortage of time, the docking 
analysis of this group was not performed.  
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Table 4.20: Experimental result of MS compounds. 
Comp. IC 50  (in mM) 
MEA2 Low a  
MEA3 Low a  
MTA8 4.411x10 11−  
MTA8AC 0.0324 
SZA1 Low a  
SZA4 Low a  
MTA9 Low a  
NOTES:  a due to the low activities the IC 50  values were not possible to calculate; 























A large number of reported thermolysin inhibitors are dipeptides [52, 145, 152-158]. 
Thermolysin is very much susceptible towards peptide bonds, and therefore dipeptides can 
easily occupy the catalytic site. A number of small organic molecules are also found to inhibit 
thermolysin. These molecules are most often derivatives of phosphate [145, 147, 159-161],  
silicon [136, 162], or sulfate [145]. Several surveys have suggested that, the major and a large 
number of the thermolysin inhibitors contain some common fragments,that bind the catalytic 
zinc ion. Nishino and Powers suggested that the oxygen atoms present in these fragments are 
forming bidentate bonds with the catalytic zinc ion [163-165].  The present docking studies 
indicate that, other atoms like sulfate (ligand 7) and nitrogen (ligand RM19) also may form 
part of bidentate bonds. Geometries of potential bidentate arrangments at zinc binding site are 
depicted in Figure 5.1. Other single interactions like Zn-O (ligand 2, 6, MS09, MS12, almost 
all RS compounds) and Zn-S (ligand 3, 4) are also common. The multiple zinc coordination 
geometries play a critical role in the stability of the metalloproteinase inhibitor complex [166]. 
 
 
Figure 5.1: Geometry of bidentate arrangements of zinc binding sites. A: Bidentate arrangements of carboxylate 
groups give rise to a four membered chelate ring (such as ligands 22, 23, 24, 25). B: Bidentate arrangements of 
phosphate oxygens groups giving a four membered chelate ring (such as ligands 12, 17, 19, 20, 21).. C: 
Bidentate arrangements of silanediols groups giving a four membered chelate ring (such as ligand 1).  D: 
Bidentate arrangements of OCNN group (ligand RM19) giving a five membered chelate ring. E: Bidentate 
arrangements of OCCS group (ligand 7) giving a five membered chelate ring.  
 
Extensive studies of flexible ligand docking accuracy using different programs have 
been reported [101, 122, 123, 144, 167, 168]. Features like, crystallographic resolution of 
docking target, starting conformation of ligand, number of rotatable bond, conformational 
space of active site topologies water accessibility, placement of polar hydrogen, correct form 
of histidine, charged or uncharged form of ligand(s) and amino acid residues within the active 
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site have been comprehensively mentioned as factors influencing docking accuracy, and need 
to be taken account during docking. In this section we have endeavored to discover more 
features that might lead to incorrect predictions. According to Hu [144] who docked 40 zinc-
dependent metalloproteinase/ligand complexes with known crystal structures, the actually 
delocalized charges (+2e) of zinc on the coordinating atoms was unintentionally used as full 
charge in every docking method, so that the total energy of zinc-ligand binding was 
overestimated due to overestimated electrostatic interactions. Not having restraints between 
the zinc ion and the inhibitor atom replacing the water molecule may be another problem. 
Adekoya mentioned in one of his studies that the inhibitor atom coordinating the zinc ion 
drifts away from the active site in the course of molecular dynamic simulations when restrains 
are not used [45].  
 
Table 5.1: Docking successfulness measured by RMSD from the X-ray crystallographic structure of the complex. 










  Program <2.0 Å <1.0 Å Metal Zinc <2.0 Å <1.0 Å 
Autodock 46 % 24 % 9/37 9/37 1/9 / 
Dock 30 % 8 % 9/37 9/37 1/9 / 
FlexX 35 % 11 % 9/37 9/37 2/9 / 
ICM 76 % 41 % 9/37 9/37 5/9 2/9 
Bursulaya 
et al.,2003 
GOLD 46 % 22 % 9/37 9/37 3/9 / 
FlexX 43 % 26 % 42/164 34/164 / / 
GOLD 55 % 39 % 42/164 34/164 / / 
GLIDE 63 % 49 % 42/164 34/164 / / 
Chen et 
al., 2006 
ICM 91 % 56 % 42/164 34/164 / / 
Autodock 40 % / 40 40 16/40 / 
Dock 20 % / 40 40 8/40 / 
FlexX 35 % / 40 40 14/40 / 
DrugScore 40 % / 40 40 16/40 / 
Xin Hu et 
al.,2004 
GOLD 53 % / 40 40 21/40 / 
 
The ability of different docking programs to reproduce the X-ray crystallographic 
conformation of native ligand within a metal ion containing binding pocket was reassessed in 
three comparative studies (Table 5.1). Table 5.1 shows that 9 and 40 metal containing targets 
were evaluated by Bursulaya [122] and Hu, respectively. The docked complexes with RMSD 
values <2Ǻ showed relatively poor performance ranging from 1 to 5 out of 9 by Bursulaya, 
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and 8 to 21 out of 40 by Hu. These rates were surprisingly low, indicating that docking 
programs often failed to find the correct binding mode in the presence of metal ion within 
active site. However, both Bursulaya and Chen [123] found relative high overall docking 
accuracy for the ICM program (76% and 91% respectively) with RMSD <2 Å. However, 
more than 70% of the tested targets did not have metal ions at the active site, indicating that 
the metal ion at the active site is a problem for docking studies. Based on these facts, we can 
say that Chen and Bursulay's relatively high docking accuracy was a direct result of a low 
number of metal containing targets. Upon this careful examination, we can conclude that a 
possible source of discrepancy that might rationalize the observed difference in success rates 
of different docking program could, arguably, be ascribed both to the lack of experience in 
how to get the best out of the program and the management of metal ion within the binding 
site. This would serve to exaggerate the difference in ICM performance between other 
docking programs. But clearly, there are potentially many other reasons: versions of the code 
used, the definition of the binding site, the human element in the study, and so on. However, 
as Hu suggested, using constrains between zinc and ZBG, the correct binding mode could be 
predicted more easily.  
It is believed that, when an inhibitor replaces the zinc bound water, particularly in 
thermolysin, the coordinated atom occupies a similar position as the water oxygen [65]. This 
may be utilized as another clue to predict binding poses. Traditionally, considering the 
chemical repulsion to small ligand in solution and irrelevant with binding, waters outside the 
binding site are deleted before docking. Examining the water molecules around bound ligands 
in crystal structures shows that waters molecules may appear in the region of the ligand. 
Moreover, these waters bare distance below 3 Å between ketone or carboxyl oxygen of the 
ligands, which indicating strong hydrogen bond interaction and that they may influence the 
ligand position. Table 5.2 shows the water molecules within Van der Waal distance around 
ligand atoms, and distance between ligand atoms and water molecules. The sRMSD relative 
to the corresponding water molecules in other X-ray structures are also given. Each of 5 
complexes (1y3g, 1thl, 1os0, 1qf0 and 1qf2) had water molecule corresponding to water173 






























a_5tmn.i/1/o1  a_5tmn.w173/173/o 2.6 a_6tmn.w167/167/o  0.22 
A_5tmn.i/^L4/o  a_5tmn.w173/173/o 2.6     
a_5tmn.i/^L4/oxt a_5tmn.w171/171/o 2.6     
5tmn 
A_5tmn.i/2/o1 a_5tmn.w28/28/o  2.7 a_6tmn.w29/29/o 0.06 
A_6tmn.i/2/o1  a_6tmn.w29/29/o 2.9     
a_6tmn.i/1/o1  a_6tmn.w167/167/o 2.6     6tmn 
a_6tmn.i/^L4/o  a_6tmn.w167/167/o 2.4     
a_1y3g.i/1/o  a_1y3g.w108/606/o 2.8 a_5tmn.w173/173/o  0.84 
1y3g 
a_1y3g.i/^L3/o a_1y3g.w108/606/o 2.5 a_6tmn.w167/167/o   0.71 
a_1thl.m7/^W322/o  a_1thl.w137/500/o  2.7 a_5tmn.w173/173/o  2.02 
1thl 
a_1thl.m7/^W322/oxt   a_1thl.w143/506/o 2.6 a_5tmn.w171/171/o 1.17 
a_1os0.m/^F3/o   a_1os0.w186/586/o 2.8 a_1thl.w137/500/o  1.2 
a_1os0.m/^F3/oxt   a_1os0.w93/493/o 2.5 a_1thl.w143/506/o 0.89 
a_1os0.m/1/o2p  a_1os0.w70/470/o  2.9 a_6tmn.w29/29/o  0.13 
1os0 
      a_5tmn.w173/173/o  1.01 
a_1qf0.ti2/317/o3  a_1qf0.w67/393/o  2.8 a_5tmn.w173/173/o  1.11 
a_1qf0.ti2/317/oxt  a_1qf0.w131/457/o 2.9 a_5tmn.w171/171/o 2.47 1qf0 
a_1qf0.ti2/317/oxt  a_1qf0.w90/416/o  2.7     
a_1qf1.ti1/317/o3  a_1qf1.w87/413/o 2.8 a_1qf0.w67/393/o  0.68 
a_1qf1.ti1/317/oxt  a_1qf1.w152/478/o 2.8 a_1qf0.w131/457/o  0.51 1qf1 
a_1qf1.ti1/317/oxt   a_1qf1.w133/459/o 2.9 a_1qf0.w90/416/o  0.4 
 a_1qf2.ti3/317/o2  a_1qf2.w216/543/o 2.9 a_5tmn.w173/173/o  0.5 
1qf2 
a_1qf2.ti3/317/oxt  a_1qf2.w216/543/o 3     
 
5.1 25 ligands from literature 
Despite the tedious calculating during the first docking of 25 ligands, the first time 
docking played major rule in exploring and seeking the ideal docking method for 
theromolysin. Due to some bad interaction between ligand and zinc ion (spotted atomic 
impact in cpk representation mode) were among the best ranked poses, these poses were 
subjected to further refinement method.  
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Although we found the elimination of those bad interactions after refinement, the 
deviation of Cal ΔG from Exp.ΔG were even more obvious after refinements for most of the 
ligands (Table 4.1). Regression analysis showed that the relationship between experimental 
and predicted inhibition (experimental and predicted ΔG values after refinement, shown in 
Table 4.1) of the molecules were not linear (R2 = 0.1874), thus indicated that the refinement 
may have induced more errors, and therefore the docking approach was modified. 
Eight X-ray crystal structure complexes of thermolysin with ligand are available in the 
PDB-database. These were analyzed to investigate the trends in geometrical and stereo-
chemical binding patterns of the ligands, and especially the ZBG. The observations were 
helpful in improving the prediction of ligand binding poses, and provide valuable guideline 
for screening thermolysin inhibitors, and formed the basis of reclassifying the 25 ligands 
according to their similarity of to one of the crystal structures.  
Ligands from the 8 X-ray crystal complexes were then docked into thermolysin in the 
conformation seen in the X-ray complexes. In this way we could also investigate the 
dependence of the starting geometry on the docked conformation. However the initial 
geometry of the ligand never explicitly enters as a docked conformation due to changing of 
bond angles during the adding of hydrogen atoms and geometry optimizing process before 
docking. Phosphorus based protease inhibitors are acidic, with pKa values of 1,4-3.1 [169], 
and therefore carry a negative charge at physiological pH, while dialkylsilanediols (SiO 2 H 2 ) 
are less acidic, with pKa near 10-12, and neutral at pH 7-7.4 [136]. All ligands from the 8 X-
ray complexes were, except 1y3g, therefore docked in a ionized form. 
It is well known from the literature that small inhibitors could be accurately docked by 
most docking software, while docking of larger compounds (i.e., those with extended 
aromatic cycles or long aliphatic chains) was more problematic [101, 123, 167]. The results 
may also depend on the starting geometries of the ligand. The native ligands extracted directly 
from the X-ray complexes and optimized by MMFF generally had less RMSD from the ligand 
in the X-ray complexes than those manually designed (by comparing average RMSD with 
previous RMSD between Table 3 & 4). The calculated RMSDs in this docking result were 
based on heavy (non-hydrogen) atoms of the ligand; furthermore it is between two selected 
chemical (hetero) molecules according to the optimal chemical match but without 3D 
superposition of the ligands. In terms of flexibility, it is well accepted that the accuracy of any 
docking program decreases with the number of rotatable bonds of the ligand. As expected, 
RMSD from X-ray complexes increase with ligand flexibility (Table 4.4 and 4.5). However, it 
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is quite modest for sets of ligands having 8-13 rotatable bonds in this study (Fig 4.3 & 4.4).  
There is less RMSD from X-ray complex within 5 rounds of docking for each inhibitor with 
neturaled Glu143 group. Generally, both with charged and neutral Glu143, the docking 
successfulness seemed to be increased (comparing with previous RMSD value). Lignads with 
rotatable bonds >13 had slightly less average RMSD from the X-ray crystal structure with 
charged Glu143 than with neutral Glu143. On the contrary, ligands with number of rotatable 
bonds <13 had average RMSD more similar to X-ray complexes with neutral Glu143. For 
both approaches, docking energy inclined to decrease as the number of rotatable bond in 
ligands increased (Fig 4.1 & 4.2). Except a slightly decrease of average energy with neutral 
Glu143 group, there was not dramatic individual energy difference between each docking 
approaches. Five and six membered rings, as well as tryptophan group in 1thl are generally 
well predicted in both methods (Figure 4.29.2). Generally, neualizing the Glu143 seemed to 
result in slight improvement in poses prediction, but docking energies with both charged and 
neutral Glu143 groups were not correlating with experimental pKi values.  
The large number of interactions between the ligand and the target (Table 4.9), 
contribute to the specificity of an enzyme for different ligands and discriminate between small 
differences in the structure of the ligand leading to a range of Ki values of ligand enzyme 
interaction. Experimental Ki values of the ligand in 5tmn and 6tmn complexes tell us that 
TLN can discriminate between very small changes in ligand structure. Example of 5tmn and 
6tmn also indicates that a nitrogen instead of an oxygen increased binding affinity. In general, 
bidentate arrangements of phosphate oxygens (compound 2, 14, 15, 16, 17, 19, 20 and 22), 
silanediols (compound 1 and 18) and OCCS (compound 5, 6 and 7) groups inhibit down to 
the nanomolar concentration range. These consistencies in affinities may arise from a better 
fit of those bidentate groups to the thermolysin active site zinc, compared with the fit of Zn-O 
(ketone) and Zn-S (sulfate). It is now well established that the combination of these moiety 
and a specific amino acid or peptide moiety in the same molecule may result in potent 
inhibitors of metallopeptidases [170].  
Besides thermolysin, this strategy has also been successfully utilized in the design of 
inhibitors for a variety of enzymes such as angiotensin-converting enzyme (ACE) [58, 171], 
carboxypeptidase A and B [172, 173] and neutral endopeptidase (NEP) [52]. Unfortunately 
this properties was not well discriminated in modified docking method since the difference in 
docking energy (such as the docking energy differences of 5tmn and 6tmn in Table 4.8) was 
not as dramatic as experimental K i values indicated .  
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We assume that correct geometry of the coordination bonds between the ZBG  and the 
catalytic zinc is important for docking accuracy and scoring reliability [144]. If ICM could 
impose constraints on the ZBG ( e.g., by requiring that ZBG group atoms are coordinated to 
Zinc at the position that most of ZBG repeatedly occur) may improve the satisfaction of 
targeted protein interactions and speeds up the calculations by reducing the size of the 
conformational space that needs to be examined [101]. The protein data bank does not store 
any information about covalent bond types and formal charges of the chemical compounds 
interacting with proteins. It is therefore impossible to automatically convert those molecules 
to anything sensible and manual interactive assignment of bond types and formal charges for 
each compound in a pdb-entry is required. Therefore, apply formal charges, MMFF and bond 
type, as well as optimize conformation is necessary before docking. There are also some 
pitfalls by using ICM: Inaccurate target model, or incorrectly converted ligands, or 
insufficient optimization effort may lead to incorrect predictions. 
As we have seen in the present study, parameterization of metal ions is a problem for 
docking studies. Metal ions as zinc may have several coordination numbers, and this is not 
taken directly into account by the docking program. Special treatment is necessary. In this 
case, consideration must also be taken into account with respect to specific interactions with 
the enzyme concerning the active site and inhibitor properties.  In short, rational design of the 
active site to generate changes in enzyme ligand interaction requires understanding and 
balancing of the basic properties of the amino acid side chains and bound ligand. 
 
5.2 In vitro assay 
Experimental assay is well recognized as golden standard to test computer predicted 
binding affinities. It provides high throughput screening of samples which enables us to 
determine IC50 values from low concentrations of putative inhibitors. Although in general, 
fluorescent assay is much more sensitive than spectrophotometric assays, our method in this 
study showed its economical, efficient and cost worthy side. Besides, fluorescent assay can 
suffer from interference caused by impurities and the instability of many fluorescent 
compounds when exposed to light. The modified spectrophotometric method of Feder and 
Schuck [135] offer several advantages over conventional spectrophotometric assays. The 
requirement for small sample volumes allows for repeated sample analysis, and multiple 
samples within 96-well microplate instead of single curette can be analyzed simultaneously in 
a short time period. But still, results using this method should be interpreted with caution due 
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to several influencing factors. These factors can be such as the degradation of DMSO 
solubilized compounds due to moisture absorbed from air [174], and changing of sample 
concentration due to evaporation of alcohol in buffer. Generally, fairly elaborate workup of 
sampling, timing and controlling of the temperature and buffer concentration may need to an 
undue loss of sensitivity and accuracy.  
5.3 R compounds 
The interaction of ligands with enzymes result in multiple contacts with the amino acids 
surrounding the binding pocket, so that only small space is left between the protein and the 
ligand and only part of the ligand is exposed to the solvent. Unlike the 25 ligands from 
literatures, most active R compounds bare monodenate Zn-O arrangement. The average Zn-O 
distance for the R compounds was 2.26Å which is very close to the Zn-O distance of 
2.01± 0.11 Å of monodenate carboxylate [65]. This, together with hydrophobic interaction 
contributed to the close packing of TLN and most active R compounds. Especially for 
compound RSH57, ZBG binding may contribute significantly to the predicted binding energy 
(-9.69 kcal/mol). Hu also mentioned in his study that for cases with good ZBG binding, the 
energy contributions from the zinc/ligand interactions amounted up to 20% of the total 
energies. He also suggested that improved scoring function, may alleviate a generally poor 
binding mode prediction [144]. In fact, the packing is even closer than illustrated in these 
figures as the space filling structures were generated taking into account only the van der 
Waals radii of atoms other than hydrogen. This close packing leads to strong bonding arising 
from van der Waals contacts due to the complementary surfaces, the formation of hydrogen 





Figure 5.2: Space filling representation shows how the RS17 (left) and RSH57 (right) occupy the binding 
pockets (grey grid mode). Amino acids forming hydrophobic interactions with RS17 and RSH57 are shown.  
 
The fluorinated inhibitors or bio-compounds have displayed a number of interesting 
physico-chemical and biological properties which made them very attractive in drug 
discovery or carrying, targeting and delivering devices [175, 176]. The rules of fluorines were 
summarized as below: 
1. The fluorinated bio-compounds were found to enhance the hydrophobic interaction, 
exhibit anti-HIV activity and contribute to increased binding affinity [175, 177, 178]. 
In a study by E.J, Jacobsen, a similar nonfluorinated analog of inhibitor had led to 40-
fold lower potency for stromelysin (a member of matrix metalloproteinase) [179]. This 
may be one of the reasons that caused very low IC50 value for compound RS17 in 
which contains hydrophobic group trifluoromethyl.  
2. Combining fluorine showed dramatic improvement in oral activity in the pleural 
cavity assay, and increased protein binding as well as potency [180]. 
Thirty-eight fluorine or trifluoromethyl substructures containing EC3 (Hydrolase 
Nomenclature of enzyme) [181] enzyme-inhibitor complexes were retrieved from protein data 
bank and studied (Table 5.1). All complexes contained EC3 hydrolases. Eight of them have 
ligand-metal ion interaction. Fluorine group populated either outside binding pocket, or 
surrounded by several hydrophobic side chains of local residues. This indication was used as a 
guide to screen out unfavorable poses appeared during docking stack conformations. From 
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Figrue 5.2 we know that the trifluoromethyl group in RS17 is not essential for binding, so it 
point towards the solvent. 
 









Interaction of F 
with metal 
1ad8 Na No No 
1b0e Ca No No 
1b0f No No No 
1bma Ca No No 
1eas Na No No 
1eat Na No No 
1eld Ca No No 
1fdk Ca yes, P atom No 
1fx9 Ca yes, P atom No 
1fxf Ca yes, P atom No 
1gg6 No No No 
1hbj No No No 
1hn4 Ca No No 
1mmj No No No 
1vsn No No No 
1xe5 No No No 
1xe6 No No No 
1y6o Ca No No 
1yl1 Ca No No 
2cng Mg No No 
2fj0 No No No 
2fm0 Zn yes, O atom No 
2fm5 Zn yes, O atom No 
1hfs Zn and Ca yes, 2O atoms No 
1usn Zn and Ca yes, S atom No 
2fog Ca No No 
2foh Ca No No 
2fq9 No No No 
2fra No No No 
2h9y No No No 
2i0u Ca No No 
2iit No No No 
2ow1 Zn and Ca Yes, 2O atoms No 
2v96 No No No 
2v97 No No No 
2v98 No No No 
6gch No No No 




5.4 MS compounds 
A significant correlation between experimental binding affinities and computed score 
was found for this group of compounds (Table 4.14). The initial docking indicated that all 
compounds of this series could bind thermolysin. However, the experimental verification 
showed that only two compounds were binders. The cause of inactive among most MS 
compounds is not currently clear, but probably due to the difference in the reaction conditions 
and toxicity to thermolysin. Hashida suggested in his study that an inhibitor may inhibit 
thermolysin activity not only as a competitive inhibitor but also by promoting autolysis [153]. 
Calcium is considered to be crucial for the thermal stability of thermolysin [182], especially 
Calcium 4 is related to the autolysis [183]. Therefore, the toxicity of MS compounds to 
thermolysin may be induced by eliminating the Ca2+ by a conformational change induced by 
the interaction of MS compounds with thermolysin. We also speculate that the bulky structure 
itself may also keep zinc binding ketone group away from interacting distance. The kinetic 
and time dependent studies (data not shown in this study) showed that, M9 is a competitive 
and fast inhibitor; where as M12 is an uncompetitive and slow inhibitor of thermolysin [150]. 

















 The ability of ICM in this study to reproduce the X-ray crystallographic conformation of 
native ligand at the active site of thermolysin was 63% (5 best ranked docking poses out of 8 
X-ray complexes had sRMSD values < 2Å). 12 out of 37 R-compounds inhibited thermolysin 
with varying IC50 values [151]. MS9 was found as competitive inhibitor of thermolysin, while 
MS12 is an uncompetitive and slow inhibitor of thermolysin. 2 out of 7 M compounds had the 
thermolysin inhibition property, and one of them was very potent inhibitor, with IC50 value of 
4,411x10-11 mM.  
If an answer to a scientist’s question does not exist in the literature, a computed 
answer is often better than no answer. Ultimately, docking program should be able to identify 
novel potential ‘binders’ very accurately. However, to reach this goal, many issues, including 
those discussed throughout this study, and scoring the binding to the metal have to be 
addressed. Specific metal binding term may need to be developed. Overall, this study 
indicates that a certain degree of improvement has been achieved both in docking and in 
experimental methodology and in both cases the technology developed for ICM and inhibition 
assay appears to provide the most consistent benefits. An interesting proposal would be to set 
up constrains between zinc and zinc-binding group of putative inhibitors (namely, template 
docking method). This may guides the binding of ligands to zinc and speeds up the 
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